


# Reference Data

(Consolidated Financial Results for Q3 FY2023)



Daiichi-Sankyo

January 31, 2024

Daiichi Sankyo Co., Ltd.

<https://www.daiichisankyo.com>

# Contents

1.	Consolidated Statement of Profit or Loss	P1
2.	Sheet to adjust Operating Profit to Core Operating Profit	P2
3.	Revenue of Global Products	P3
4.	Revenue by Business Units and Products	P5
5.	Consolidated Statement of Financial Position	P8
6.	Consolidated Statement of Cash Flows	P10
7.	Number of Employees	P11
8.	Capital Expenditure, Depreciation and Amortization	P11
9.	Summary of Product Outlines	P12
10.	Quarterly Data	P13
11.	Historical Data	P19
12.	Major R&D Pipeline (Innovative pharmaceuticals)	P23

# 1. Consolidated Statement of Profit or Loss

JPY Bn	FY2022 Q3 YTD		FY2023 Q3 YTD					FY2023							
	to revenue	Results	to revenue	Results	(vs. Forecast (%))	YoY	YoY (%)	to revenue	Forecast (as of Apr.)	to revenue	Forecast (as of Oct.)	to revenue	Forecast (as of Jan.)	vs. Forecast (as of Oct.)	
<b>Revenue</b>	100.0%	<b>948.3</b>	100.0%	<b>1,173.3</b>	74.3%	<b>225.0</b>	<b>+23.7%</b>		<b>100.0%</b>	<b>1,450.0</b>	100.0%	<b>1,550.0</b>	100.0%	<b>1,580.0</b>	<b>30.0</b>
Cost of sales**1	27.1%	257.4	26.4%	310.3	75.1%	52.9	+20.6%	Forex impact: +40.0 (USD: +16.5, EUR: +19.1, ASCA: +4.4)	27.6%	400.0	26.5%	410.0	26.1%	413.0	3.0
Gross Profit	72.9%	690.9	73.6%	863.0	73.9%	172.1	+24.9%	Forex impact: +8.9 (USD: +4.5, EUR: +4.0, ASCA: +0.4)	72.4%	1,050.0	73.5%	1,140.0	73.9%	1,167.0	27.0
SG&A expenses**1	34.9%	330.8	37.0%	433.9	70.1%	103.1	+31.2%	Forex impact: +16.0 (USD: +9.9, EUR: +4.9, ASCA: +1.1)	37.9%	550.0	39.4%	610.0	39.2%	619.0	9.0
R&D expenses**1	25.5%	241.7	21.9%	256.8	69.8%	15.1	+6.2%	Forex impact: +9.9 (USD: +7.0, EUR: +2.7, ASCA: +0.2)	24.8%	360.0	24.2%	375.0	23.3%	368.0	-7.0
<b>Core Operating Profit</b>	<b>12.5%</b>	<b>118.3</b>	<b>14.7%</b>	<b>172.2</b>	<b>95.7%</b>	<b>53.9</b>	<b>+45.5%</b>	Forex impact: +5.3 (USD: -4.8, EUR: +7.5, ASCA: +2.7)	<b>9.7%</b>	<b>140.0</b>	<b>10.0%</b>	<b>155.0</b>	<b>11.4%</b>	<b>180.0</b>	<b>25.0</b>
Temporary income**2		11.0		26.9		15.8				-		-		27.0	27.0
Temporary expenses**2		2.2		4.6		2.3				5.0		5.0		7.0	2.0
<b>Operating Profit</b>	<b>13.4%</b>	<b>127.1</b>	<b>16.6%</b>	<b>194.6</b>	<b>97.3%</b>	<b>67.4</b>	<b>+53.0%</b>		<b>9.3%</b>	<b>135.0</b>	<b>9.7%</b>	<b>150.0</b>	<b>12.7%</b>	<b>200.0</b>	<b>50.0</b>
Financial income/expenses		0.4		5.2		4.8		- Increase of interest income +9.6 - Improvement in investment securities valuation gains/losses +5.3 - Deterioration in forex gains/losses -9.3				10.0		5.0	-5.0
Share of profit or loss of investments accounted for using the equity method		-0.1		0.1		0.2									
<b>Profit before tax</b>	<b>13.4%</b>	<b>127.5</b>	<b>17.0%</b>	<b>199.8</b>	<b>97.5%</b>	<b>72.4</b>	<b>+56.8%</b>		<b>9.3%</b>	<b>135.0</b>	<b>10.3%</b>	<b>160.0</b>	<b>13.0%</b>	<b>205.0</b>	<b>45.0</b>
Income taxes		40.8		35.7		-5.0									
<b>Profit for the year</b>	<b>9.1%</b>	<b>86.7</b>	<b>14.0%</b>	<b>164.1</b>	<b>93.8%</b>	<b>77.4</b>	<b>+89.3%</b>		<b>7.9%</b>	<b>115.0</b>	<b>8.7%</b>	<b>135.0</b>	<b>11.1%</b>	<b>175.0</b>	<b>40.0</b>
<b>Profit attributable to owners of the Company</b>	<b>9.1%</b>	<b>86.7</b>	<b>13.9%</b>	<b>163.6</b>	<b>93.5%</b>	<b>76.9</b>	<b>+88.7%</b>		<b>7.9%</b>	<b>115.0</b>	<b>8.7%</b>	<b>135.0</b>	<b>11.1%</b>	<b>175.0</b>	<b>40.0</b>
Tax rate		32.0%		17.9%											
Overseas sales ratio		56.5%		59.5%											
Currency Rate (Average)									Currency Rate	Currency Rate	Currency Rate				
USD/JPY		136.53		143.29					130.00	143.00	143.72				
EUR/JPY		140.60		155.28					140.00	154.19	155.21				

(Assumption of currency rate for Q4)  
USD/JPY 145, EUR/JPY 155

## Annual impact of JPY 1 change

	Forecast	
	USD	EUR
Revenue	JPY 3.5 Bn	JPY 1.8 Bn
Operating Profit	JPY -0.4 Bn	JPY 0.5 Bn

\*This report is not subject to audit procedures.

※1 Temporary income and expenses are excluded for cost of sales, SG&A expenses and R&D expenses

※2 See page 2 for the definition of temporary income and expenses and the adjustment of operating profit and core operating profit

## 2. Sheet to adjust Operating Profit to Core Operating Profit

### FY2022 Q3 YTD Results

JPY Bn	Full base	Adjustment					Core base
		gains and losses related to sale of fixed assets	gains and losses related to restructuring	gains and losses related to impairment,	gains and losses related to loss compensation, reconciliation	Others	
<b>Revenue</b>	<b>948.3</b>						<b>948.3</b>
Cost of sales	257.5					-0.1	257.4
SG&A expenses	330.8			-0.0		-0.0	330.8
R&D expenses	240.4			1.5		-0.2	241.7
Other income*	8.1	-1.8	-6.0			-0.3	-
Other expenses*	0.5		-0.5				-
<b>Core Operating Profit**</b>							<b>118.3</b>
Temporary income		1.8	6.0 <sup>*1</sup>	3.3 <sup>*2</sup>			11.0
Temporary expenses			0.5	1.8 <sup>*3</sup>			2.2
<b>Operating Profit (full)</b>	<b>127.1</b>						<b>127.1</b>

<Major Temporary income and Temporary expenses>

<sup>\*1</sup> Gains on sale of a subsidiary in China

<sup>\*2</sup> Gains on reversal related to the closure of PLX

<sup>\*3</sup> Losses related to impairment of Intangible assets (Pentrox etc.)

### FY2023 Q3 YTD Results

JPY Bn	Full base	Adjustment					Core base
		gains and losses related to sale of fixed assets	gains and losses related to restructuring	gains and losses related to impairment,	gains and losses related to loss compensation, reconciliation	Others	
<b>Revenue</b>	<b>1,173.3</b>						<b>1,173.3</b>
Cost of sales	310.8			-0.4		-0.1	310.3
SG&A expenses	437.9					-4.0	433.9
R&D expenses	257.1		-0.2			-0.0	256.8
Other income*	27.1	-0.1			-26.8	-0.2	-
Other expenses*	0.0	-0.0					-
<b>Core Operating Profit**</b>							<b>172.2</b>
Temporary income		0.1			26.8 <sup>*4</sup>		26.9
Temporary expenses		0.0	0.2	0.4		3.9	4.6
<b>Operating Profit (full)</b>	<b>194.6</b>						<b>194.6</b>

<Major Temporary income and Temporary expenses>

<sup>\*4</sup> Settlement payment for Plexxikon

related to patent dispute with Novartis (26.1)

\* The Company discloses profit and loss for which the offsetting of income and expenses is not permitted as Other income and Other expenses in the consolidated statement of income on a full basis (IFRS standards). Profit and loss from the sale of assets, etc. are included in this Other income and Other expenses.

\*\* As an indicator of ordinary profitability, "core operating profit" which excludes temporary income and expenses from operating income is disclosed. Gains and losses related to: sale of fixed assets, restructuring (excluding the sales of pipeline and launched products), impairment, loss compensation, reconciliation, and other non-temporary and material gains and losses are included in the "temporary income and expenses".

### 3. Revenue of Global Products (1)

JPY Bn	FY2022 Q3 YTD	FY2023 Q3 YTD				FY2023					
		Results	Results	(vs. Forecast (%))	YoY	YoY (%)	Forecast (as of Apr.)	Forecast (as of Oct.)	Forecast (as of Jan.)	vs. Forecast (as of Oct.)	YoY
<b>Trastuzumab deruxtecan</b> anti-cancer agent (HER2-directed antibody drug conjugate)	<b>167.6</b>	<b>294.4</b>	<b>(67.4%)</b>	<b>126.8</b>	<b>+75.6%</b>	<b>368.6</b>	<b>433.6</b>	<b>436.5</b>	<b>2.9</b>	<b>178.1</b>	<b>+68.9%</b>
Product sales *Incl. Gross profit share in AstraZeneca territory	139.7	276.0	(71.9%)	136.3	+97.5%	320.0	381.7	383.9	2.2	176.3	+85.0%
Enhertu (JPN)	8.5	17.7	(77.7%)	9.2	+108.8%	19.9	21.5	22.8	1.3	11.1	+94.7%
Enhertu (US)	99.8	162.8	(71.9%)	63.0	+63.1%	195.1	229.5	226.3	-3.2	81.7	+56.5%
Enhertu (EU)	22.3	64.7	(68.5%)	42.4	+190.3%	75.8	92.8	94.5	1.7	57.5	+155.1%
Enhertu (ASCA: Asia, South and Central America)	9.2	30.8	(76.4%)	21.6	+235.8%	29.2	37.8	40.3	2.4	26.1	+183.8%
Upfront payment	7.4	7.6	(74.8%)	0.2	+2.6%	9.8	9.8	10.1	0.3	0.3	+2.9%
Regulatory milestone payment	19.7	10.0	(80.9%)	-9.7	-49.2%	11.6	11.9	12.4	0.4	-14.3	-53.7%
US HER2+ Breast Cancer 3L	0.7	0.7	(74.8%)	0.0	+2.6%	0.9	0.9	0.9	0.0	0.0	+3.0%
EU HER2+ Breast Cancer 3L	0.4	0.4	(74.8%)	0.0	+2.6%	0.5	0.5	0.5	0.0	0.0	+3.0%
US HER2+ Gastric Cancer 2L/3L	0.6	0.6	(74.8%)	0.0	+2.6%	0.8	0.8	0.8	0.0	0.0	+3.0%
US HER2+ Breast Cancer 2L	3.2	0.7	(74.8%)	-2.6	-79.5%	0.9	0.9	0.9	0.0	-2.6	-74.3%
EU HER2+ Breast Cancer 2L	2.5	0.5	(74.8%)	-2.0	-79.5%	0.7	0.7	0.7	0.0	-2.0	-74.3%
US HER2-low Breast Cancer (post chemo)	6.8	1.4	(74.8%)	-5.4	-79.5%	1.8	1.8	1.9	0.1	-5.4	-74.3%
EU HER2-low Breast Cancer (post chemo)	-	1.0	(74.8%)	1.0	-	1.3	1.3	1.3	0.0	-3.9	-74.3%
EU HER2+ Gastric Cancer 2L	1.2	0.2	(74.8%)	-0.9	-79.5%	0.3	0.3	0.3	0.0	-0.9	-74.3%
US HER2 mutant NSCLC 2L	4.3	0.9	(74.8%)	-3.4	-79.5%	1.1	1.1	1.2	0.0	-3.4	-74.3%
EU HER2 mutant NSCLC 2L	-	3.6	(95.0%)	3.6	-	3.2	3.6	3.8	0.2	3.8	-
Quid related payment*	0.9	0.9	(74.8%)	0.0	+2.6%	1.1	1.1	1.2	0.0	0.0	+3.0%
Sales milestone payment	-	-	-	-	-	26.0	29.0	29.0	-	15.8	+120.0%
*Payment which shall be paid by AstraZeneca to Daiichi Sankyo if both parties do not enter into potential licensing opportunity (Granting Daiichi Sankyo rights to develop or commercialize AstraZeneca's proprietary products, programs or technologies)											
<b>Datopotamab deruxtecan</b> anti-cancer agent (TROP2-directed antibody drug conjugate)	<b>5.5</b>	<b>4.8</b>	<b>(75.0%)</b>	<b>-0.7</b>	<b>-12.7%</b>	<b>6.4</b>	<b>6.4</b>	<b>6.4</b>	<b>-</b>	<b>-0.7</b>	<b>-9.8%</b>
Upfront payment	5.5	4.8	(75.0%)	-0.7	-12.7%	6.4	6.4	6.4	-	-0.7	-9.8%

### 3. Revenue of Global Products (2)

JPY Bn		FY2022 Q3 YTD	FY2023 Q3 YTD				FY2023						
		Results	Results	(vs. Forecast (%))	YoY	YoY (%)	Forecast (as of Apr.)	Forecast (as of Oct.)	Forecast (as of Jan.)	vs. Forecast (as of Oct.)	YoY	YoY (%)	
	<b>Patritumab deruxtecan</b>	anti-cancer agent (HER3-directed antibody drug conjugate)	-	<b>1.6</b>	<b>(44.3%)</b>	<b>1.6</b>	-	-	-	<b>3.5</b>	<b>3.5</b>	<b>3.5</b>	-
	Upfront payment		-	1.6	(44.3%)	1.6	-	-	-	3.5	3.5	3.5	-
	<b>Ifinatumab deruxtecan</b>	anti-cancer agent (B7-H3-directed antibody drug conjugate)	-	<b>2.9</b>	<b>(44.3%)</b>	<b>2.9</b>	-	-	-	<b>6.6</b>	<b>6.6</b>	<b>6.6</b>	-
	Upfront payment		-	2.9	(44.3%)	2.9	-	-	-	6.6	6.6	6.6	-
	<b>Raludotatug deruxtecan</b>	anti-cancer agent (CDH6-directed antibody drug conjugate)	-	<b>1.2</b>	<b>(44.3%)</b>	<b>1.2</b>	-	-	-	<b>2.8</b>	<b>2.8</b>	<b>2.8</b>	-
	Upfront payment		-	1.2	(44.3%)	1.2	-	-	-	2.8	2.8	2.8	-
	<b>Edoxaban</b>	anticoagulant	<b>183.2</b>	<b>216.2</b>	<b>(76.7%)</b>	<b>33.0</b>	<b>+18.0%</b>	<b>259.4</b>	<b>277.3</b>	<b>281.9</b>	<b>4.6</b>	<b>37.9</b>	<b>+15.5%</b>
	Lixiana (JPN)		79.5	89.5	(78.2%)	10.0	+12.6%	109.9	112.9	114.4	1.5	9.3	+8.8%
	Savaysa (US)		1.9	2.0	(68.3%)	0.1	+4.6%	3.2	3.3	3.0	-0.3	-0.0	-0.8%
	Lixiana (EU)		87.8	107.3	(75.5%)	19.6	+22.3%	125.1	138.8	142.3	3.5	25.1	+21.5%
	Edoxaban (ASCA* etc.)		14.0	17.3	(77.7%)	3.3	+23.8%	21.2	22.4	22.2	-0.2	3.5	+18.9%

\*Asia, South and Central America

#### 4. Revenue by Business Units and Products (1)

JPY Bn	FY2022 Q3 YTD		FY2023 Q3 YTD				FY2023					
	Results		Results	(vs. Forecast (%))	YoY	YoY (%)	Forecast (as of Apr.)	Forecast (as of Oct.)	Forecast (as of Jan.)	vs. Forecast (as of Oct.)	YoY	YoY (%)
<b>Japan Business Unit</b>	<b>356.4</b>		<b>412.3</b>	<b>(80.1%)</b>	<b>55.9</b>	<b>+15.7%</b>	<b>499.4</b>	<b>499.4</b>	<b>514.7</b>	<b>15.3</b>	<b>56.8</b>	<b>+12.4%</b>
Lixiana	anticoagulant	79.5	89.5	(78.2%)	10.0	+12.6%	109.9	112.9	114.4	1.5	9.3	+8.8%
Pralia	Treatment for osteoporosis/ inhibitor of the progression of bone erosion associated with rheumatoid arthritis	30.4	33.3	(78.8%)	2.9	+9.5%	43.5	41.6	42.3	0.6	2.1	+5.2%
Tarlige	pain treatment	29.1	35.4	(78.1%)	6.3	+21.6%	41.4	45.2	45.3	0.1	6.8	+17.6%
Vimpat	anti-epileptic agent	16.7	20.0	(77.3%)	3.2	+19.2%	24.8	25.6	25.8	0.3	3.9	+17.6%
Ranmark	treatment for bone complications caused by bone metastases from tumors	15.6	15.8	(76.5%)	0.3	+1.9%	21.3	20.6	20.7	0.2	0.4	+1.8%
Tenelia	type 2 diabetes mellitus treatment	17.0	16.1	(78.5%)	-0.9	-5.1%	20.9	20.4	20.6	0.2	-1.4	-6.3%
Enhertu	anti-cancer agent (HER2-directed antibody drug conjugate)	8.5	17.7	(77.7%)	9.2	+108.8%	19.9	21.5	22.8	1.3	11.1	+94.7%
Efient	antiplatelet agent	15.7	19.7	(78.2%)	3.9	+25.1%	18.8	24.3	25.1	0.8	4.2	+20.3%
Canalia	type 2 diabetes mellitus treatment	12.5	12.5	(78.2%)	-0.1	-0.5%	17.1	15.9	15.9	0.1	-0.3	-2.1%
Loxonin	anti-inflammatory analgesic	14.7	12.5	(80.9%)	-2.3	-15.5%	16.7	15.1	15.4	0.3	-3.1	-16.9%
Emgality	prophylaxis of migraine attacks	4.7	5.7	(77.3%)	1.0	+20.3%	10.5	8.1	7.4	-0.7	1.1	+17.4%
Daiichi Sankyo Espha products		66.1	64.9	-	-1.3	-1.9%	not disclosed	not disclosed	not disclosed	-	-	-
Vaccines business		16.1	28.2	-	12.1	+74.8%	not disclosed	not disclosed	not disclosed	-	-	-
<b>Daiichi Sankyo Healthcare Unit</b>		<b>54.8</b>	<b>59.9</b>	<b>(80.3%)</b>	<b>5.1</b>	<b>+9.4%</b>	<b>74.4</b>	<b>73.1</b>	<b>74.6</b>	<b>1.5</b>	<b>4.3</b>	<b>+6.1%</b>

#### 4. Revenue by Business Units and Products (2)

JPY Bn	FY2022 Q3 YTD		FY2023 Q3 YTD				FY2023					
	Results		Results	(vs. Forecast (%))	YoY	YoY (%)	Forecast (as of Apr.)	Forecast (as of Oct.)	Forecast (as of Jan.)	vs. Forecast (as of Oct.)	YoY	YoY (%)
<b>Oncology Business Unit</b>	<b>124.7</b>		<b>233.0</b>	<b>(71.1%)</b>	<b>108.2</b>	<b>+86.8%</b>	<b>276.2</b>	<b>330.6</b>	<b>327.8</b>	<b>-2.8</b>	<b>142.4</b>	<b>+76.8%</b>
Enhertu anti-cancer agent (HER2-directed antibody drug conjugate)	122.1		227.5	(70.9%)	105.4	+86.4%	270.9	322.3	320.8	-1.5	139.2	+76.6%
Enhertu (US)	99.8		162.8	(71.9%)	63.0	+63.1%	195.1	229.5	226.3	-3.2	81.7	+56.5%
Enhertu (EU)	22.3		64.7	(68.5%)	42.4	+190.3%	75.8	92.8	94.5	1.7	57.5	+155.1%
TURALIO anti-cancer agent	2.7		4.1	(76.9%)	1.4	+54.1%	3.5	5.2	5.3	0.2	1.5	+39.9%
<b>American Regent Unit</b>	<b>143.5</b>		<b>152.0</b>	<b>(73.8%)</b>	<b>8.5</b>	<b>+5.9%</b>	<b>198.7</b>	<b>210.7</b>	<b>205.9</b>	<b>-4.8</b>	<b>18.5</b>	<b>+9.9%</b>
Injectafer treatment for iron deficiency anemia	41.8		38.0	(74.8%)	-3.8	-9.0%	52.0	51.9	50.9	-1.0	-3.1	-5.8%
Venofer treatment for iron deficiency anemia	38.2		45.2	(75.7%)	7.0	+18.4%	44.1	57.4	59.7	2.3	8.4	+16.4%
GE injectables	55.6		59.1	(72.0%)	3.5	+6.4%	87.5	88.1	82.1	-6.0	10.5	+14.7%
<b>EU Specialty Business Unit</b>	<b>112.5</b>		<b>137.6</b>	<b>(74.9%)</b>	<b>25.1</b>	<b>+22.3%</b>	<b>161.0</b>	<b>180.0</b>	<b>183.7</b>	<b>3.7</b>	<b>33.3</b>	<b>+22.1%</b>
Lixiana anticoagulant	87.8		107.3	(75.5%)	19.6	+22.3%	125.1	138.8	142.3	3.5	25.1	+21.5%
Nilemdo/Nustendi cholesterol-lowering agent	4.9		12.1	(66.6%)	7.2	+147.1%	15.9	18.3	18.1	-0.2	11.0	+156.3%
Olmесartan antihypertensive agent	14.8		14.5	(77.4%)	-0.3	-2.1%	16.3	18.6	18.8	0.1	-1.2	-6.2%
<b>ASCA Business Unit</b>	<b>106.4</b>		<b>131.8</b>	<b>(75.0%)</b>	<b>25.4</b>	<b>+23.8%</b>	<b>156.3</b>	<b>169.8</b>	<b>175.8</b>	<b>6.0</b>	<b>33.0</b>	<b>+23.1%</b>
Daiichi Sankyo China	44.7		49.8	(75.6%)	5.1	+11.4%	65.5	62.4	65.8	3.5	7.5	+12.9%
Daiichi Sankyo Korea	18.7		21.9	(72.6%)	3.2	+16.9%	25.8	30.4	30.1	-0.3	4.6	+17.9%
Daiichi Sankyo Brasil Farmacêutica	19.9		30.1	(76.1%)	10.2	+51.3%	34.0	38.5	39.6	1.1	11.8	+42.6%
Daiichi Sankyo Taiwan	9.9		12.0	(77.5%)	2.0	+20.3%	13.2	15.0	15.4	0.5	2.1	+15.9%
Daiichi Sankyo Thailand	2.1		2.6	(77.0%)	0.5	+22.5%	2.9	3.1	3.3	0.3	0.4	+15.3%
Daiichi Sankyo Hong Kong	2.5		2.3	(83.5%)	-0.2	-8.0%	2.0	2.6	2.7	0.1	-0.8	-22.3%



#### 4. Revenue by Business Units and Products (3)

##### [Reference] Revenue in Local Currency

	FY2022 Q3 YTD	FY2023 Q3 YTD				FY2023						
		Results	Results	(vs. Forecast (%))	YoY	YoY (%)	Forecast (as of Apr.)	Forecast (as of Oct.)	Forecast (as of Jan.)	vs. Forecast (as of Oct.)	YoY	YoY (%)
USD Mn												
<b>Oncology Business Unit</b>	<b>914</b>	<b>1,626</b>	<b>(71.3%)</b>	<b>712</b>	<b>+77.9%</b>	<b>2,124</b>	<b>2,312</b>	<b>2,281</b>	<b>-31</b>	<b>912</b>	<b>+66.6%</b>	
Enhertu anti-cancer agent (HER2-directed antibody drug conjugate)	894	1,588	(71.1%)	694	+77.6%	2,084	2,254	2,232	-22	892	+66.5%	
Enhertu (US)	731	1,136	(72.2%)	405	+55.4%	1,500	1,605	1,575	-30	507	+47.5%	
Enhertu (EU)	163	452	(68.7%)	288	+176.6%	583	649	658	8	384	+140.5%	
TURALIO anti-cancer agent	19	29	(77.1%)	9	+46.9%	27	36	37	1	9	+31.9%	
USD Mn												
<b>American Regent Unit</b>	<b>1,051</b>	<b>1,061</b>	<b>(74.1%)</b>	<b>9</b>	<b>+0.9%</b>	<b>1,529</b>	<b>1,474</b>	<b>1,433</b>	<b>-41</b>	<b>50</b>	<b>+3.6%</b>	
Injectafer treatment for iron deficiency anemia	306	265	(75.0%)	-41	-13.3%	400	363	354	-9	-44	-11.2%	
Venofer treatment for iron deficiency anemia	280	315	(75.9%)	36	+12.9%	339	402	416	14	37	+9.8%	
GE injectables	407	413	(72.3%)	5	+1.3%	673	616	571	-45	43	+8.1%	
EUR Mn												
<b>EU Specialty Business Unit</b>	<b>800</b>	<b>886</b>	<b>(74.9%)</b>	<b>86</b>	<b>+10.8%</b>	<b>1,150</b>	<b>1,167</b>	<b>1,183</b>	<b>16</b>	<b>116</b>	<b>+10.9%</b>	
Lixiana anticoagulant	624	691	(75.4%)	67	+10.7%	894	900	917	17	86	+10.3%	
Nilemdo/Nustendi cholesterol-lowering agent	35	78	(66.6%)	43	+123.7%	114	119	117	-2	67	+132.8%	
Olmesartan antihypertensive agent	105	94	(77.3%)	-12	-11.3%	116	121	121	0	-21	-14.8%	

## 5. Consolidated Statement of Financial Position

<Assets>

JPY Bn

	Mar. 2023	Dec. 2023	vs. Mar. 2023	
Assets				
Current assets				
Cash and cash equivalents	441.9	666.7	224.8	
Trade and other receivables	349.1	458.6	109.5	
Other financial assets	383.2	534.3	151.1	
Inventories	301.6	391.2	89.6	
Other current assets	19.2	48.5	29.2	
Subtotal	1,495.1	2,099.3	604.3	
Assets held for sale	-	18.3	18.3	Transfer of DSEP assets held for sale +18.3
<b>Total current assets</b>	<b>1,495.1</b>	<b>2,117.6</b>	<b>622.5</b>	
Non-current assets				
Property, plant and equipment	348.9	394.7	45.8	Acquisition +67.2, Depreciation -29.1, Forex +8.5
Goodwill	98.3	103.0	4.7	Forex +4.7
Intangible assets	159.6	148.4	-11.2	Acquisition +4.8, Depreciation -14.2, Forex +6.8, Transfer to Assets held for sale (DSEP) -8.7
Investments accounted for using the equity method	1.3	0.5	-0.8	
Other financial assets	130.4	149.5	19.1	Investment securities +21.3
Deferred tax assets	180.1	196.9	16.8	
Other non-current assets	95.2	158.2	63.0	Contribution for equipment +60.4
<b>Total non-current assets</b>	<b>1,013.8</b>	<b>1,151.4</b>	<b>137.5</b>	
<b>Total assets</b>	<b>2,508.9</b>	<b>3,268.9</b>	<b>760.1</b>	
* Liquidity on hand (Cash, Securities, Investment securities etc.)	824.4	1,200.7	376.3	
Debt with interest	192.9	154.0	-38.9	
Net Cash	631.5	1,046.7	415.2	

## &lt;Liabilities and equity&gt;

JPY Bn

	Mar. 2023	Dec. 2023	vs. Mar. 2023	
<b>Liabilities</b>				
Current liabilities				
Trade and other payables	395.2	456.3	61.1	
Bonds and borrowings	41.4	0.4	-41.0	Bonds -20.0, Short-term borrowings -21.0
Other financial liabilities	11.1	11.6	0.5	
Income taxes payable	21.5	36.2	14.7	
Provisions	7.6	8.3	0.7	
Contract liabilities	28.9	58.8	30.0	
Other current liabilities	24.7	22.8	-1.9	
Subtotal	530.3	594.4	64.1	
Liabilities directly associated with assets held for sale	-	12.4	12.4	Transfer of liabilities associated with DSEP assets held for sale +12.4
<b>Total current liabilities</b>	<b>530.3</b>	<b>606.8</b>	<b>76.5</b>	
Non-current liabilities				
Bonds and borrowings	101.7	101.4	-0.3	
Other financial liabilities	41.6	44.9	3.3	
Post employment benefit liabilities	1.3	1.7	0.4	
Provisions	16.4	16.0	-0.4	Deferred revenue for trastuzumab deruxtecan -7.3 (Strategic collaboration upfront payment -7.6, Regulatory milestone payment/Quid +0.2)
Contract liabilities	292.2	694.4	402.2	Deferred revenue for datopotamab deruxtecan -4.8 (Strategic collaboration upfront payment -4.8)
Deferred tax liabilities	12.6	12.9	0.3	Deferred revenue related to strategic collaboration with MRK: Merck & Co., Inc., Rahway, NJ, USA +445.0 (Upfront payment)
Other non-current liabilities	66.9	203.6	136.8	R&D expenses related refundable upfront payment from MRK +150.3
<b>Total non-current liabilities</b>	<b>532.8</b>	<b>1,075.0</b>	<b>542.3</b>	
<b>Total liabilities</b>	<b>1,063.0</b>	<b>1,681.8</b>	<b>618.8</b>	
<b>Equity</b>				
Equity attributable to owners of the Company				
Share capital	50.0	50.0	-	
Capital surplus	-	1.3	1.3	
Treasury shares	-36.8	-36.7	0.1	
Other components of equity	200.9	241.8	40.9	Currency translation difference +32.6, Valuation difference on financial assets +8.7
Retained earnings	1,231.8	1,329.9	98.1	Profit for the period +163.6, Payment of dividends -67.1
Total equity attributable to owners of the Company	1,445.9	1,586.3	140.5	
Non-controlling interests	-	0.8	0.8	
<b>Total equity</b>	<b>1,445.9</b>	<b>1,587.1</b>	<b>141.3</b>	
<b>Total liabilities and equity</b>	<b>2,508.9</b>	<b>3,268.9</b>	<b>760.1</b>	

## 6. Consolidated Statement of Cash Flows

JPY Bn

	FY2022Q3 YTD	FY2023Q3 YTD	YoY
Cash flows from operating activities			
Profit before tax	127.5	199.8	72.4
Depreciation and amortization	46.1	43.5	-2.6
(Increase) decrease in receivables and payables	-62.6	-9.4	53.1
Others, net	3.5	402.5	399.0
Income taxes paid	-32.3	-67.1	-34.8
<b>Net cash flows from operating activities</b>	<b>82.1</b>	<b>569.3</b>	<b>487.2</b>
Cash flows from investing activities			
Net (increase) decrease in time deposits and securities	-204.8	-142.3	62.5
(Acquisition of) proceeds from sales of fixed assets	-48.7	-75.4	-26.7
Payments for acquisition of subsidiaries	-31.0	-6.9	24.1
Proceeds from sale of subsidiaries	8.4	7.5	-0.9
Net (increase) decrease in investment securities	-0.4	-1.7	-1.2
Others, net	1.1	-0.5	-1.6
<b>Net cash flows from investing activities</b>	<b>-275.5</b>	<b>-219.2</b>	<b>56.2</b>
Cash flows from financing activities			
Net (increase) decrease in borrowings	-20.3	-21.3	-1.0
Repayments of bonds	-	-20.0	-20.0
Purchase of treasury shares	-0.0	-0.0	0.0
Dividends paid	-54.7	-67.1	-12.5
Others, net	-10.8	-11.3	-0.4
<b>Net cash flows from financing activities</b>	<b>-85.8</b>	<b>-119.7</b>	<b>-33.9</b>
<b>Net increase (decrease) in cash and cash equivalents</b>	<b>-279.1</b>	<b>230.3</b>	<b>509.5</b>
<b>Cash and cash equivalents at the beginning of the period</b>	<b>662.5</b>	<b>441.9</b>	<b>-220.6</b>
<b>Effect of exchange rate changes on cash and cash equivalents</b>	<b>11.8</b>	<b>0.8</b>	<b>-11.0</b>
<b>Cash and cash equivalents at the end of the period</b>	<b>395.2</b>	<b>673.1</b>	<b>277.9</b>
<b>Transfer to Assets held for sale</b>	<b>-</b>	<b>-6.3</b>	<b>-6.3</b>
<b>Cash and cash equivalents at the end of the period (Amount on Consolidated Statement of Financial Position)</b>	<b>395.2</b>	<b>666.7</b>	<b>271.6</b>
<b>* Free cash flows (Cash flows from operating activities and investing activities)</b>	<b>-193.3</b>	<b>350.1</b>	<b>359.5</b>

Payment from MRK +601.0  
(Upfront payment, R&D expenses related refundable upfront payment)

## 7. Number of Employees

	Dec. 2022	Mar. 2023	Dec. 2023
	Results	Results	Results
Consolidated	17,236	17,435	18,390
Japan	9,264	9,263	9,452
North America	3,019	3,062	3,443
Europe	2,493	2,554	2,800
Others	2,460	2,556	2,695

## 8. Capital Expenditure, Depreciation and Amortization

		FY2022 Q3 YTD	FY2022	FY2023 Q3 YTD	FY2023
	JPY Bn	Results	Results	Results	Forecast
Capital expenditure		49.2	71.5	61.5	48.5
Depreciation and amortization		46.1	67.8	43.5	57.0
Property, plant and equipment		27.0	36.3	29.2	-
Intangible assets		19.1	31.4	14.3	-

## 9. Summary of Product Outlines

Brand Name	Generic Name	Therapeutic Category	Launched	Origin	Marketing Alliance	Type of Alliance
<b>Japan Business Unit</b>						
Lixiana	edoxaban	anticoagulant	2011	Daiichi Sankyo		
Tarlige	mirogabalin	pain treatment	2019	Daiichi Sankyo		
Pralia	denosumab	treatment for osteoporosis/ inhibitor of the progression of bone erosion associated with rheumatoid arthritis	2013	Amgen		
Efient	prasugrel	antiplatelet agent	2014	Daiichi Sankyo Ube Industries		
Tenelia	teneligliptin	type 2 diabetes mellitus treatment	2012	Mitsubishi Tanabe	Mitsubishi Tanabe	Co-promotion (DS: Sales)
Vimpat	lacosamide	anti-epileptic agent	2016	UCB	UCB	Co-promotion (DS: Sales)
Ranmark	denosumab	treatment for bone complications caused by bone metastases from tumors	2012	Amgen		
Canalia	teneligliptin / canagliflozin	type 2 diabetes mellitus treatment	2017	Mitsubishi Tanabe	Mitsubishi Tanabe	Co-promotion (DS: Sales)
Loxonin			1986	Daiichi Sankyo		
Loxonin Poultice	loxoprofen	anti-inflammatory analgesic	2006	Lead Chemical		
Loxonin Tape			2008	Lead Chemical		
Loxonin Gel			2010	Daiichi Sankyo		
Enhertu	trastuzumab deruxtecan	anti-cancer agent (HER2-directed antibody drug conjugate)	2020	Daiichi Sankyo		
Emgality	galcanezumab-gnlm	Prophylaxis of migraine attacks	2021	Eli Lilly Japan	Eli Lilly Japan	Co-promotion (DS: Sales)
<b>Oncology Business Unit</b>						
Enhertu	trastuzumab deruxtecan	anti-cancer agent (HER2-directed antibody drug conjugate)	2020	Daiichi Sankyo	AstraZeneca	Co-promotion (DS: Sales)
Turalio	pexidartinib	anti-cancer agent	2019	Daiichi Sankyo		
<b>American Regent Unit</b>						
Injectafer	ferric carboxymaltose injection	treatment for iron deficiency anemia	2013	CSL Vifor	Daiichi Sankyo, Inc.	Promotion (Daiichi Sankyo, Inc.)
Venofer	iron sucrose injection	treatment for iron deficiency anemia	2000	CSL Vifor	Fresenius	Co-marketing
<b>EU Specialty Business Unit</b>						
Lixiana	edoxaban	anticoagulant	2015	Daiichi Sankyo	Merck (MSD)	Co-marketing
Nilemdo/Nustendi	bempedoic acid, bempedoic acid / ezetimibe	cholesterol-lowering agent	2020	Esperion		
Olmesartan						
Olmetec	olmesartan		2002			
Olmetec Plus	olmesartan / hydrochlorothiazide	antihypertensive agent	2005	Daiichi Sankyo	Menarini Pfizer	Co-marketing
Sevikar	olmesartan / amlodipine		2009			
Sevikar HCT	olmesartan / amlodipine / hydrochlorothiazide		2010			

<10. Quarterly Data>

**1. Consolidated Statement of Profit or Loss**

JPY Bn	FY2022	FY2022	FY2022	FY2022	FY2022		FY2023	FY2023	FY2023	FY2023	FY2023			
	Q1	Q2	Q3	Q4	to revenue	Results	Q1	Q2	Q3	Q4	to revenue	Results	YoY	YoY (%)
	Results	Results	Results	Results			Results	Results	Results	Results				
<b>Revenue</b>	<b>280.3</b>	<b>327.5</b>	<b>340.5</b>	<b>330.2</b>	<b>100.0%</b>	<b>1,278.5</b>	<b>350.8</b>	<b>375.5</b>	<b>446.9</b>	<b>-</b>	<b>100.0%</b>	<b>1,173.3</b>	<b>225.0</b>	<b>+23.7%</b>
Cost of sales	74.7	84.7	98.0	91.7	27.3%	349.1	93.6	94.8	122.0	-	26.4%	310.3	52.9	+20.6%
Gross Profit	205.6	242.8	242.5	238.5	72.7%	929.4	257.2	280.8	325.0	-	73.6%	863.0	172.1	+24.9%
SG&A expenses	96.3	113.4	121.1	139.3	36.8%	470.1	135.6	141.0	157.3	-	37.0%	433.9	103.1	+31.2%
R&D expenses	74.9	78.9	87.9	95.0	26.3%	336.7	77.2	88.9	90.8	-	21.9%	256.8	15.1	+6.2%
<b>Core Operating Profit</b>	<b>34.4</b>	<b>50.4</b>	<b>33.6</b>	<b>4.3</b>	<b>9.6%</b>	<b>122.6</b>	<b>44.5</b>	<b>50.9</b>	<b>76.9</b>	<b>-</b>	<b>14.7%</b>	<b>172.2</b>	<b>53.9</b>	<b>+45.5%</b>
Temporary income	0.0	10.8	0.2	10.9		21.9	0.5	0.2	26.2	-		26.9	15.8	
Temporary expenses	-	0.0	2.2	21.7		23.9	0.9	0.0	3.6	-		4.6	2.3	
<b>Operating Profit</b>	<b>34.4</b>	<b>61.2</b>	<b>31.6</b>	<b>-6.6</b>	<b>9.4%</b>	<b>120.6</b>	<b>44.0</b>	<b>51.0</b>	<b>99.5</b>	<b>-</b>	<b>16.6%</b>	<b>194.6</b>	<b>67.4</b>	<b>+53.0%</b>
Financial income/expenses	-4.9	0.7	4.7	5.9		6.3	8.1	-1.1	-1.8	-		5.2	4.8	
Share of profit or loss of investments accounted for using the equity method	-0.0	-0.0	-0.0	0.1		-0.0	0.0	0.0	0.0	-		0.1	0.2	
<b>Profit before tax</b>	<b>29.4</b>	<b>61.8</b>	<b>36.2</b>	<b>-0.6</b>	<b>9.9%</b>	<b>126.9</b>	<b>52.1</b>	<b>50.0</b>	<b>97.7</b>	<b>-</b>	<b>17.0%</b>	<b>199.8</b>	<b>72.4</b>	<b>+56.8%</b>
Income taxes	10.6	22.4	7.8	-23.1		17.7	-4.9	10.0	30.7	-		35.7	-5.0	
<b>Profit for the year</b>	<b>18.9</b>	<b>39.5</b>	<b>28.4</b>	<b>22.5</b>	<b>8.5%</b>	<b>109.2</b>	<b>57.0</b>	<b>40.0</b>	<b>67.1</b>	<b>-</b>	<b>14.0%</b>	<b>164.1</b>	<b>77.4</b>	<b>+89.3%</b>
<b>Profit attributable to owners of the Company</b>	<b>18.9</b>	<b>39.5</b>	<b>28.4</b>	<b>22.5</b>	<b>8.5%</b>	<b>109.2</b>	<b>57.0</b>	<b>40.0</b>	<b>66.6</b>	<b>-</b>	<b>13.9%</b>	<b>163.6</b>	<b>76.9</b>	<b>+88.7%</b>
Tax rate	35.9%	36.2%	21.5%	-		13.9%	-9.4%	20.0%	31.4%			17.9%		
Overseas sales ratio	55.4%	58.1%	55.8%	63.4%		58.3%	60.9%	60.0%	57.8%			59.5%		
Currency Rate (YTD Average)														
USD/JPY	129.57	138.38	141.64	132.32		135.48	137.37	144.63	147.89			143.29		
EUR/JPY	138.10	139.34	144.35	142.07		140.97	149.46	157.29	159.10			155.28		

<b>2. Revenue of Global Products (1)</b>	<b>FY2022 Q1</b>	<b>FY2022 Q2</b>	<b>FY2022 Q3</b>	<b>FY2022 Q4</b>	<b>FY2022</b>	<b>FY2023 Q1</b>	<b>FY2023 Q2</b>	<b>FY2023 Q3</b>	<b>FY2023 Q4</b>	<b>FY2023</b>
JPY Bn	Results	Results	Results	Results	Results	Results	Results	Results	Results	Results
<b>Trastuzumab deruxtecan</b>	<b>37.4</b>	<b>64.4</b>	<b>65.8</b>	<b>90.7</b>	<b>258.4</b>	<b>86.6</b>	<b>96.5</b>	<b>111.4</b>	<b>-</b>	<b>294.4</b>
Product sales	31.3	48.2	60.2	67.8	207.5	81.7	91.6	102.6	-	276.0
Enhertu(JPN)	2.4	2.8	3.3	3.2	11.7	4.4	6.0	7.3	-	17.7
Enhertu (US)	20.0	35.3	44.5	44.8	144.6	51.6	54.3	57.0	-	162.8
Enhertu (EU)	6.7	7.0	8.6	14.8	37.1	17.8	21.4	25.5	-	64.7
Enhertu (ASCA: Asia, South and Central America)	2.2	3.2	3.8	5.0	14.2	8.0	9.9	12.8	-	30.8
Upfront payment	2.5	2.5	2.5	2.5	9.8	2.5	2.5	2.6	-	7.6
Regulatory milestone payment	3.4	13.5	2.9	7.0	26.7	2.1	2.1	5.8	-	10.0
US HER2+ Breast Cancer 3L	0.2	0.2	0.2	0.2	0.9	0.2	0.2	0.2	-	0.7
EU HER2+ Breast Cancer 3L	0.1	0.1	0.1	0.1	0.5	0.1	0.1	0.1	-	0.4
US HER2+ Gastric Cancer 2L/3L	0.2	0.2	0.2	0.2	0.8	0.2	0.2	0.2	-	0.6
US HER2+ Breast Cancer 2L	2.8	0.2	0.2	0.2	3.5	0.2	0.2	0.2	-	0.7
EU HER2+ Breast Cancer 2L	-	2.3	0.2	0.2	2.7	0.2	0.2	0.2	-	0.5
US HER2-low Breast Cancer (post chemo)	-	6.4	0.5	0.5	7.3	0.5	0.5	0.5	-	1.4
EU HER2-low Breast Cancer (post chemo)	-	-	-	5.2	5.2	0.3	0.3	0.4	-	1.0
EU HER2+ Gastric Cancer 2L	-	-	1.2	0.1	1.3	0.1	0.1	0.1	-	0.2
US HER2 Mutant NSCLC 2L	-	4.0	0.3	0.3	4.6	0.3	0.3	0.3	-	0.9
EU HER2 Mutant NSCLC 2L	-	-	-	-	-	-	-	3.6	-	3.6
QUID related payment	0.3	0.3	0.3	0.3	1.1	0.3	0.3	0.3	-	0.9
Sales milestone payment	-	-	-	13.2	13.2	-	-	-	-	-
<b>Datopotamab deruxtecan</b>	<b>1.5</b>	<b>2.4</b>	<b>1.6</b>	<b>1.6</b>	<b>7.1</b>	<b>1.6</b>	<b>1.6</b>	<b>1.6</b>	<b>-</b>	<b>4.8</b>
Upfront payment	1.5	2.4	1.6	1.6	7.1	1.6	1.6	1.6	-	4.8



<b>2. Revenue of Global Products (2)</b>	<b>FY2022 Q1</b>	<b>FY2022 Q2</b>	<b>FY2022 Q3</b>	<b>FY2022 Q4</b>	<b>FY2022</b>	<b>FY2023 Q1</b>	<b>FY2023 Q2</b>	<b>FY2023 Q3</b>	<b>FY2023 Q4</b>	<b>FY2023</b>
JPY Bn	Results	Results	Results	Results	Results	Results	Results	Results	Results	Results
<b>Patritumab deruxtecan</b>	-	-	-	-	-	-	-	1.6	-	1.6
Upfront payment	-	-	-	-	-	-	-	1.6	-	1.6
<b>Ifinatamab deruxtecan (DS-7300)</b>	-	-	-	-	-	-	-	2.9	-	2.9
Upfront payment	-	-	-	-	-	-	-	2.9	-	2.9
<b>Raludotatug deruxtecan (DS-6000)</b>	-	-	-	-	-	-	-	1.2	-	1.2
Upfront payment	-	-	-	-	-	-	-	1.2	-	1.2
<b>Edoxaban</b>	<b>58.9</b>	<b>58.4</b>	<b>65.9</b>	<b>60.8</b>	<b>244.0</b>	<b>66.0</b>	<b>71.7</b>	<b>78.5</b>	-	<b>216.2</b>
Lixiana (JPN)	25.1	25.6	28.8	25.6	105.1	27.9	29.3	32.4	-	89.5
Savaysa (US)	0.6	0.9	0.5	1.1	3.0	0.5	1.1	0.5	-	2.0
Lixiana (EU)	28.6	27.2	32.0	29.3	117.1	32.3	35.6	39.4	-	107.3
Edoxaban (ASCA* etc.)	4.6	4.7	4.7	4.7	18.7	5.3	5.8	6.2	-	17.3

\*Asia, South and Central America

<b>3. Revenue by Business Units and Products (1)</b>	<b>FY2022 Q1</b>	<b>FY2022 Q2</b>	<b>FY2022 Q3</b>	<b>FY2022 Q4</b>	<b>FY2022</b>	<b>FY2023 Q1</b>	<b>FY2023 Q2</b>	<b>FY2023 Q3</b>	<b>FY2023 Q4</b>	<b>FY2023</b>
JPY Bn	Results	Results	Results	Results	Results	Results	Results	Results	Results	Results
<b>Japan Business Unit</b>	<b>109.0</b>	<b>116.0</b>	<b>131.3</b>	<b>101.5</b>	<b>457.9</b>	<b>119.0</b>	<b>127.8</b>	<b>165.5</b>	<b>-</b>	<b>412.3</b>
Lixiana	25.1	25.6	28.8	25.6	105.1	27.9	29.3	32.4	-	89.5
Pralia	9.9	9.4	11.1	9.8	40.2	10.7	10.4	12.2	-	33.3
Tarlige	8.9	9.4	10.8	9.4	38.5	11.7	11.0	12.6	-	35.4
Vimpat	5.3	5.3	6.1	5.2	21.9	6.4	6.3	7.2	-	20.0
Ranmark	4.9	5.1	5.5	4.8	20.4	5.0	5.3	5.6	-	15.8
Tenelia	5.6	5.4	6.0	4.9	21.9	5.3	5.1	5.7	-	16.1
Enhertu	2.4	2.8	3.3	3.2	11.7	4.4	6.0	7.3	-	17.7
Efient	4.9	5.0	5.8	5.2	20.9	6.1	6.3	7.3	-	19.7
Canalia	4.1	4.0	4.4	3.8	16.3	4.1	4.0	4.3	-	12.5
Loxonin	4.6	4.8	5.3	3.8	18.5	4.0	4.0	4.5	-	12.5
Emgality	1.4	1.6	1.7	1.5	6.3	1.7	1.8	2.1	-	5.7
Daiichi Sankyo Espha products	21.0	20.9	24.3	19.9	86.0	20.6	20.6	23.7	-	64.9
Vaccines business	0.5	8.1	7.5	-2.7	13.4	0.7	7.5	20.0	-	28.2
<b>Daiichi Sankyo Healthcare Unit</b>	<b>15.3</b>	<b>18.4</b>	<b>21.2</b>	<b>15.6</b>	<b>70.3</b>	<b>17.1</b>	<b>20.3</b>	<b>22.5</b>	<b>-</b>	<b>59.9</b>

<b>3. Revenue by Business Units and Products (2)</b>	<b>FY2022 Q1</b>	<b>FY2022 Q2</b>	<b>FY2022 Q3</b>	<b>FY2022 Q4</b>	<b>FY2022</b>	<b>FY2023 Q1</b>	<b>FY2023 Q2</b>	<b>FY2023 Q3</b>	<b>FY2023 Q4</b>	<b>FY2023</b>
JPY Bn	Results	Results	Results	Results	Results	Results	Results	Results	Results	Results
<b>Oncology Business Unit</b>	<b>27.5</b>	<b>43.2</b>	<b>54.0</b>	<b>60.7</b>	<b>185.4</b>	<b>70.6</b>	<b>78.2</b>	<b>84.1</b>	<b>-</b>	<b>233.0</b>
Enhertu	26.7	42.3	53.1	59.6	181.6	69.4	75.7	82.4	-	227.5
Enhertu (US)	20.0	35.3	44.5	44.8	144.6	51.6	54.3	57.0	-	162.8
Enhertu (EU)	6.7	7.0	8.6	14.8	37.1	17.8	21.4	25.5	-	64.7
Turalio	0.8	0.9	0.9	1.1	3.8	1.2	1.4	1.5	-	4.1
<b>American Regent Unit</b>	<b>47.0</b>	<b>47.1</b>	<b>49.4</b>	<b>43.8</b>	<b>187.4</b>	<b>50.7</b>	<b>48.0</b>	<b>53.3</b>	<b>-</b>	<b>152.0</b>
Injectafer	14.1	13.3	14.4	12.1	54.0	13.2	12.5	12.3	-	38.0
Venofer	12.4	12.6	13.1	13.1	51.3	15.8	13.3	16.1	-	45.2
GE injectables	17.6	18.8	19.2	16.0	71.6	18.3	19.0	21.8	-	59.1
<b>EU Specialty Business Unit</b>	<b>37.1</b>	<b>34.7</b>	<b>40.7</b>	<b>37.9</b>	<b>150.4</b>	<b>41.5</b>	<b>44.9</b>	<b>51.2</b>	<b>-</b>	<b>137.6</b>
Lixiana	28.6	27.2	32.0	29.3	117.1	32.3	35.6	39.4	-	107.3
Nilemdo/Nustendi	1.3	1.5	2.1	2.2	7.1	3.0	3.8	5.2	-	12.1
Olmesartan	5.4	4.4	5.0	5.2	20.0	4.7	4.5	5.3	-	14.5
<b>ASCA Business Unit</b>	<b>31.9</b>	<b>37.9</b>	<b>36.6</b>	<b>36.3</b>	<b>142.8</b>	<b>39.5</b>	<b>43.6</b>	<b>48.7</b>	<b>-</b>	<b>131.8</b>
Daiichi Sankyo China	13.3	16.9	14.4	13.6	58.3	15.5	15.2	19.0	-	49.8
Daiichi Sankyo Korea	6.1	6.2	6.3	6.8	25.6	6.3	8.3	7.3	-	21.9
Daiichi Sankyo Brasil Farmacêutica	4.8	7.4	7.8	7.8	27.8	8.9	10.0	11.3	-	30.1
Daiichi Sankyo Taiwan	3.1	3.3	3.5	3.4	13.3	4.0	3.9	4.1	-	12.0
Daiichi Sankyo Thailand	0.6	0.7	0.8	0.8	2.9	0.8	0.8	0.9	-	2.6
Daiichi Sankyo Hong Kong	0.6	0.9	0.9	1.0	3.5	1.1	0.5	0.6	-	2.3

<b>3. Revenue by Business Units and Products (3)</b>	<b>FY2022 Q1</b>	<b>FY2022 Q2</b>	<b>FY2022 Q3</b>	<b>FY2022 Q4</b>	<b>FY2022</b>	<b>FY2023 Q1</b>	<b>FY2023 Q2</b>	<b>FY2023 Q3</b>	<b>FY2023 Q4</b>	<b>FY2023</b>
<b>[Reference] Revenue in Local Currency</b>	Results	Results	Results	Results	Results	Results	Results	Results	Results	Results
USD Mn										
<b>Oncology Business Unit</b>	<b>212</b>	<b>315</b>	<b>386</b>	<b>455</b>	<b>1,369</b>	<b>514</b>	<b>541</b>	<b>570</b>	<b>-</b>	<b>1,626</b>
Enhertu	206	309	379	447	1,341	505	524	559	-	1,588
Enhertu (US)	155	258	318	336	1,067	375	375	385	-	1,136
Enhertu (EU)	52	50	61	110	274	130	149	173	-	452
Turalio	6	7	7	9	28	9	9	10	-	29
USD Mn										
<b>American Regent Unit</b>	<b>363</b>	<b>340</b>	<b>349</b>	<b>332</b>	<b>1,383</b>	<b>369</b>	<b>331</b>	<b>361</b>	<b>-</b>	<b>1,061</b>
Injectafer	109	96	102	92	398	96	86	83	-	265
Venofer	96	91	93	99	379	115	92	109	-	315
GE injectables	136	136	136	121	529	133	131	148	-	413
EUR Mn										
<b>EU Specialty Business Unit</b>	<b>269</b>	<b>249</b>	<b>282</b>	<b>267</b>	<b>1,067</b>	<b>278</b>	<b>286</b>	<b>323</b>	<b>-</b>	<b>886</b>
Lixiana	207	195	222	207	831	216	226	249	-	691
Nilemdo/Nustendi	10	11	14	15	50	20	24	33	-	78
Olmesartan	39	32	35	37	142	32	28	33	-	94

## <11. Historical Data>

### 1. Revenue of Global Products

	FY2018	FY2019	FY2020	FY2021	FY2022
JPY Bn	Results	Results	Results	Results	Results
<b>Trastuzumab deruxtecan</b>	<b>0.1</b>	<b>14.0</b>	<b>43.5</b>	<b>80.8</b>	<b>258.4</b>
Product sales	-	3.2	30.1	65.4	207.5
Enhertu (JPN)	-	-	4.4	9.6	11.7
Enhertu (US)	-	3.2	25.7	45.4	144.6
Enhertu (EU)	-	-	0.0	9.0	37.1
Enhertu (ASCA: Asia, South and Central America)	-	-	-	1.4	14.2
Upfront payment	0.1	9.8	9.8	9.8	9.8
Regulatory milestone payment	-	0.9	3.5	2.2	26.7
US HER2+ Breast Cancer 3L	-	0.9	0.9	0.9	0.9
EU HER2+ Breast Cancer 3L	-	-	1.0	0.5	0.5
US HER2+ Gastric Cancer 2L/3L	-	-	1.6	0.8	0.8
US HER2+ Breast Cancer 2L	-	-	-	-	3.5
EU HER2+ Breast Cancer 2L	-	-	-	-	2.7
US HER2-low Breast Cancer (post chemo)	-	-	-	-	7.3
EU HER2-low Breast Cancer (post chemo)	-	-	-	-	5.2
EU HER2+ Gastric Cancer 2L	-	-	-	-	1.3
US HER2 Mutant NSCLC 2L	-	-	-	-	4.6
EU HER2 Mutant NSCLC 2L	-	-	-	-	-
QUID related payment	-	-	-	3.4	1.1
Sales milestone payment	-	-	-	-	13.2
<b>Datopotamab deruxtecan</b>	<b>-</b>	<b>-</b>	<b>3.9</b>	<b>6.1</b>	<b>7.1</b>
Upfront payment	-	-	3.9	6.1	7.1
<b>Edoxaban</b>	<b>117.7</b>	<b>154.0</b>	<b>165.9</b>	<b>205.6</b>	<b>244.0</b>
Lixiana (JPN)	64.9	83.0	77.4	92.5	105.1
Savaysa (US)	2.3	2.6	3.0	1.9	3.0
Lixiana (EU)	45.8	61.7	76.7	96.9	117.1
Other subsidiaries	4.7	6.8	8.9	14.3	18.7

**2. Revenue by Business Units and Products (1)**

	FY2018	FY2019	FY2020	FY2021	FY2022
JPY Bn	Results	Results	Results	Results	Results
<b>Japan Business Unit</b>	<b>523.3</b>	<b>533.5</b>	<b>489.1</b>	<b>489.5</b>	<b>457.9</b>
Lixiana	64.9	83.0	77.4	92.5	105.1
Pralia	27.4	30.9	34.6	37.9	40.2
Tarlige	-	8.0	20.6	30.1	38.5
Vimpat	6.6	11.2	14.5	18.3	21.9
Ranmark	16.4	17.9	19.3	20.4	20.4
Tenelia	25.3	24.7	24.2	23.7	21.9
Enhertu	-	-	4.4	9.6	11.7
Efient	13.9	14.0	14.1	16.7	20.9
Canalia	9.2	12.8	15.4	16.8	16.3
Loxonin	30.5	28.3	24.2	22.2	18.5
Emgality	-	-	-	4.6	6.3
Inavir	18.2	19.3	3.6	1.3	1.1
Daiichi Sankyo Espha products	55.5	60.5	71.4	82.8	86.0
Vaccines business	41.5	35.6	18.5	14.8	13.4
<b>Daiichi Sankyo Healthcare Unit</b>	<b>66.4</b>	<b>68.5</b>	<b>67.2</b>	<b>64.7</b>	<b>70.3</b>

## 2. Revenue by Business Units and Products (2)

	FY2018	FY2019	FY2020	FY2021	FY2022
JPY Bn	Results	Results	Results	Results	Results
<b>Oncology Business Unit</b>	<b>36.3</b>	<b>32.1</b>	<b>47.4</b>	<b>69.6</b>	<b>185.4</b>
Enhertu	-	3.2	25.7	54.4	181.6
Enhertu (US)	-	3.2	25.7	45.4	144.6
Enhertu (EU)	-	-	0.0	9.0	37.1
Turalio	-	-	1.8	2.8	3.8
<b>American Regent Unit</b>	<b>117.8</b>	<b>130.8</b>	<b>121.7</b>	<b>149.5</b>	<b>187.4</b>
Injectafer	44.2	51.8	44.1	53.1	54.0
Venofer	28.9	31.0	28.8	33.8	51.3
<b>EU Specialty Business Unit</b>	<b>88.6</b>	<b>95.5</b>	<b>111.7</b>	<b>128.2</b>	<b>150.4</b>
Lixiana	45.8	61.7	76.7	96.9	117.1
Nilemdo/Nustendi	-	-	0.6	3.1	7.1
Olmesartan	27.4	24.6	21.5	20.3	20.0
<b>ASCA Business Unit</b>	<b>87.7</b>	<b>98.3</b>	<b>99.7</b>	<b>114.1</b>	<b>142.8</b>
Daiichi Sankyo China	38.5	46.0	45.6	53.3	58.3
Daiichi Sankyo Korea	15.7	17.2	19.6	23.2	25.6
Daiichi Sankyo Brasil Farmacêutica	10.0	11.5	10.5	13.7	27.8
Daiichi Sankyo Taiwan	7.1	7.6	8.3	10.0	13.3
Daiichi Sankyo Thailand	3.3	3.3	2.3	2.2	2.9
Daiichi Sankyo Hong Kong	-	-	0.7	1.7	3.5

**2. Revenue by Business Units and Products (3)****[Reference] Revenue in Local Currency**

	FY2018	FY2019	FY2020	FY2021	FY2022
	Results	Results	Results	Results	Results
USD Mn					
<b>Oncology Business Unit</b>	<b>327</b>	<b>295</b>	<b>447</b>	<b>619</b>	<b>1,369</b>
Enhertu	-	30	243	484	1,341
Enhertu (US)	-	30	243	404	1,067
Enhertu (EU)	-	-	0	80	274
Turalio	-	-	17	25	28
USD Mn					
<b>American Regent Unit</b>	<b>1,062</b>	<b>1,204</b>	<b>1,148</b>	<b>1,330</b>	<b>1,383</b>
Injectafer	399	477	416	472	398
Venofer	261	285	272	300	379
EUR Mn					
<b>EU Specialty Business Unit</b>	<b>690</b>	<b>789</b>	<b>903</b>	<b>982</b>	<b>1,067</b>
Lixiana	357	509	620	742	831
Nilemdo/Nustendi	-	-	5	24	50
Olmesartan	213	203	174	155	142



◆ Explanation of Description

Generic name/Project Code Number (mechanism of action)

Detail on its mechanism

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
<ul style="list-style-type: none"> <li>Phase of the study</li> <li>Study Name (if applicable)</li> <li>CTG registration number</li> <li>JapicCTI/jRCT registration number</li> <li>Partner (if applicable)</li> </ul>	Patients and target indications for the study	Target sample size	Study design schematic (randomize or not, blinding or not, control group or not, etc)	<ul style="list-style-type: none"> <li>Primary and secondary endpoints are listed</li> <li>Safety measures are summarized as "safety"</li> <li>Pharmacokinetic indices are summarized as "PK"</li> </ul>	Region under study (not consistent with region under development)	<ul style="list-style-type: none"> <li>Announcements as these trials open</li> <li>Scheduled time to achieve TLR (LPD if achieved)</li> <li>Schedule timing of submission for late-phase projects</li> <li>Application status, status of obtaining various review preference systems, etc.</li> </ul>

◆ List of Abbreviations

ADA: anti-drug antibody, ADC: antibody drug conjugate, AGA: actionable genomic alterations, AML: acute myeloid leukemia, BMFI: brain metastases-free interval, BMS: Bristol Myers Squibb, BOR: best overall response, BTC: biliary tract cancer, CBR: clinical benefit rate, CR: complete remission, CRL: complete response letter, DCR: disease control rate, DDFS: distant disease-free survival, DFS: disease-free survival, DOR: duration of response, DRFI: distant recurrence-free interval, EFS: event-free survival, eGFR: estimated glomerular filtration rate, FPD: first patient dosed, FSD: first subject dosed, GMFR: geometric mean fold rise, GMT: geometric mean titer, IDFS: invasive disease-free survival, LPD: last patient dosed, MLFS: morphologic leukemia-free state, MRK: Merck & Co., Inc., Rahway, NJ, USA, NSCLC: non small cell lung cancer, ORR: overall response rate/objective response rate, OS: overall survival, pCR: pathological complete response, PFS: progression-free survival, PK: pharmacokinetics, PLD: pegylated liposomal doxorubicin, PR: partial remission, PRO: patient reported outcome, SCCHN: squamous cell carcinomas of the head and neck, SCLC: small cell lung cancer, SCR: seroconversion rate, TLR: top line results, TNBC: triple negative breast cancer, TTD: Time to deterioration, TTNT: Time to next treatment, TTR: time to response, UACR: urine albumin-creatinine ratio

## ◆ 5DXd-ADCs

### Trastuzumab deruxtecan/DS-8201/T-DXd (HER2-directed ADC)

Antibody-drug conjugate which is composed of a humanized monoclonal antibody specifically targeting HER2, one of the Epidermal Growth Factor Receptor (EGFR) family proteins, and a covalently linked drug (payload) via a cleavable linker. Payload is a potent and membrane permeable DNA topoisomerase I inhibitor which enables elimination of both target tumor cells and the surrounding tumor cells. Drug-to-antibody ratio is approximately 8.

Brand name: ENHERTU (JP/US/EU/China)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 2 (registrational) DESTINY-Breast01  NCT03248492 JapicCTI-173693  AstraZeneca	HER2 positive breast cancer, 3L	253	Randomized, open label •DS-8201	Primary endpoint: ORR Secondary endpoint: ORR, DOR, PFS, OS, etc.	JP/US/EU /Asia	FPD: Oct 2017 TLR: May 2019  Jan 2020: Launch (US) May 2020: Launch (JP) Feb 2021: Launch (EU)
Phase 3 DESTINY-Breast02  NCT03523585 JapicCTI-184017  AstraZeneca	HER2 positive breast cancer, 3L	600	Randomized, open label, active control •DS-8201 •Physician's choice (trastuzumab + capecitabine or lapatinib + capecitabine)	Primary endpoint: PFS Secondary endpoint: OS, ORR, DOR, PFS, etc.	JP/US/EU /Asia	FPD: Sep 2018 TLR: Aug 2022
Phase 3 DESTINY-Breast03  NCT03529110 JapicCTI-183976  AstraZeneca	HER2 positive breast cancer, 2L	524	Randomized, open label, active control •DS-8201 •T-DM1	Primary endpoint: PFS Secondary endpoint: OS, ORR, DOR, PFS, etc.	JP/US/EU /Asia	FPD: Aug 2018 TLR: Aug 2021  May 2022: Approval (US) Jul 2022: Approval (EU) Nov 2022: Approval (JP) Feb 2023: Approval (CN)  Aug 2021: Real Time Oncology Review Designation (US) Sep 2021: Breakthrough Therapy Designation (US)

## Trastuzumab deruxtecan/DS-8201/T-DXd (HER2-directed ADC)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 3 DESTINY-Breast04  NCT03734029 JapicCTI-184223  AstraZeneca	HER2 low breast cancer, post chemotherapy	557	Randomized, open label, active control •DS-8201 •Physician's choice (capecitabine, eribulin, gemcitabine, paclitaxel or nab-paclitaxel)	Primary endpoint: PFS Secondary endpoint: OS, ORR, DOR, etc.	JP/US/EU /Asia	FPD: Dec 2018 TLR: Feb 2022  Aug 2022: Approval (US) Jan 2023: Approval (EU) Mar 2023: Approval (JP) Jul 2023: Approval (CN)  Feb 2022: Real Time Oncology Review Designation (US) Apr 2022: Breakthrough Therapy Designation (US) Aug 2022: Priority Review Designation (JP)
Phase 3 DESTINY-Breast05  NCT04622319 jRCT2061200033  AstraZeneca	HER2 positive breast cancer with residual invasive disease following neoadjuvant therapy, adjuvant therapy	1,600	Randomized, open label, active control •DS-8201 •T-DM1	Primary endpoint: IDFS Secondary endpoint: DFS, OS, DRFI, BMFI, safety, PK, etc.	JP/US/EU /Asia	FPD: Dec 2020
Phase3 DESTINY-Breast06  NCT04494425 jRCT2061200028  AstraZeneca	HER2 low/HR positive breast cancer, chemotherapy naïve	866	Randomized, open label, active control •DS-8201 •Physician's choice (capecitabine, paclitaxel or nab-paclitaxel)	Primary endpoint: PFS Secondary endpoint: OS, PFS, ORR, DOR, safety, etc.	JP/US/EU /Asia	FPD: Aug 2020 TLR anticipated: FY2024 H1
Phase1b/2 DESTINY-Breast07  NCT04538742  AstraZeneca	HER2 positive breast cancer Part 1: 2L or later Part 2: 1L	245	Open label, two-part (dose escalation, dose expansion) •DS-8201 + durvalumab •DS-8201 + pertuzumab •DS-8201 + paclitaxel •DS-8201 + durvalumab + paclitaxel •DS-8201 + tucatinib •DS-8201	Primary endpoint: Safety Secondary endpoint: ORR, PFS, DOR, OS, PK, etc.	US/EU /Asia	FPD: Jan 2021

## Trastuzumab deruxtecan/DS-8201/T-DXd (HER2-directed ADC)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase1b DESTINY-Breast08  NCT04556773  AstraZeneca	HER2 low breast cancer chemotherapy naïve, post chemotherapy	139	Open label, two-part (dose escalation, dose expansion) •DS-8201 + capecitabine •DS-8201 + durvalumab + paclitaxel •DS-8201 + capivasertib (AZD5363) •DS-8201 + anastrozole •DS-8201 + fulvestrant	Primary endpoint: safety Secondary endpoint: ORR, PFS, DOR, OS, PK, etc.	US/EU /Asia	FPD: Jan 2021
Phase3 DESTINY-Breast09  NCT04784715 jRCT2031210130  AstraZeneca	HER2 positive breast cancer, 1L	1,134	Randomized, open label, active control •DS-8201 •DS-8201 + pertuzumab •Taxane + trastuzumab + pertuzumab	Primary endpoint: PFS Secondary endpoint: OS, PFS, ORR, DOR, PK, safety, etc.	JP/US/EU /Asia	FPD: Jun 2021
Phase3 DESTINY-Breast11  NCT05113251 jRCT2041210097  AstraZeneca	HER2 positive breast cancer, neoadjuvant	900	Randomized, open label, active control •DS-8201 •DS-8201, followed by paclitaxel + trastuzumab + pertuzumab •doxorubicin + cyclophosphamide, followed by paclitaxel + trastuzumab + pertuzumab	Primary endpoint: pCR Secondary endpoint: EFS, IDFS, OS	JP/US/EU /Asia	FPD: Nov 2021
Phase 1b/2 BEGONIA  NCT03742102  AstraZeneca	TNBC	240	Non-randomized, open label, combination with durvalumab •DS-8201 + durvalumab  * Umbrella study of durvalumab led by AstraZeneca	Primary endpoint: safety Secondary endpoint: ORR, PFS, DOR, OS, PK, etc.	US/EU /Asia	FPD: May 2020
Phase 2 (registrational) DESTINY-Gastric01  NCT03329690 JapicCTI-173727  AstraZeneca	HER2 expressing, gastric or gastroesophageal junction adenocarcinoma, 3L	233	Randomized, open label, active control •DS-8201 •Physician's choice (irinotecan or paclitaxel)	Primary endpoint: ORR Secondary endpoint: PFS, OS, DOR, DCR, TTF, ORR, PK	JP/Asia	FPD: Nov 2017 TLR: Jan 2020 Sep 2020: Approval (JP) Jan 2021: Approval (US) Dec 2022: Approval (EU)  Mar 2018: SAKIGAKE Designation (JP) May 2020: Breakthrough Therapy Designation (US) May 2020: Orphan Drug Designation (US)

## Trastuzumab deruxtecan/DS-8201/T-DXd (HER2-directed ADC)

Study Name	Population	Sample size	Study Design	Evaluation Items	Region	Status
Phase 2 DESTINY-Gastric02  NCT04014075 AstraZeneca	HER2 positive gastric or gastroesophageal junction adenocarcinoma, 2L	79	Open label •DS-8201	Primary endpoint: ORR Secondary endpoint: PFS, ORR, OS, DOR	US/EU	FPD: Dec 2019 TLR: Jun 2021 Dec 2022: Approval (EU)
Phase 1b/2 DESTINY-Gastric03  NCT04379596 jRCT2031200203  AstraZeneca	HER2 positive gastric/gastroesophageal junction and esophageal adenocarcinoma Part 1: 2L Part 2: 1L Part 3: 1L	357	Randomized, open label Part 1 •DS-8201 + fluorouracil •DS-8201 + capecitabine •DS-8201 + durvalumab •DS-8201 + oxaliplatin + fluorouracil •DS-8201 + capecitabine + oxaliplatin •DS-8201 + durvalumab + fluorouracil •DS-8201 + capecitabine + durvalumab  Part 2 •DS-8201 •DS-8201 + oxaliplatin + fluorouracil or capecitabine •DS-8201 + pembrolizumab + fluorouracil or capecitabine •DS-8201 + pembrolizumab •Trastuzumab + fluorouracil or capecitabine + cisplatin or oxaliplatin  Part 3 •DS-8201 + MEDI5752 + fluorouracil or capecitabine	Primary endpoint: Part 1: safety, Part 2: ORR Secondary endpoint: ORR, safety, DOR, DCR, PFS, OS, PK, ADA	JP/US/EU /Asia	FPD: Jun 2020

## Trastuzumab deruxtecan/DS-8201/T-DXd (HER2-directed ADC)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 3 DESTINY-Gastric04  NCT04704934 jRCT2031200369  AstraZeneca	HER2 positive gastric or gastroesophageal junction adenocarcinoma, 2L	490	Randomized, open label •DS-8201 •Ramucirumab + paclitaxel	Primary endpoint: OS Secondary endpoint: PFS, ORR, DOR, DCR, safety, PK, ADA, etc.	JP/EU /Asia	FPD: Jun 2021
Phase 2 DESTINY-Gastric06  NCT04989816  AstraZeneca	HER2 positive gastric or gastroesophageal junction adenocarcinoma, 3L	95	Open label •DS-8201	Primary endpoint: ORR Secondary endpoint: ORR, PFS, DCR, DOR, OS, Tumor size change, PK, ADA	China	FPD: Sep 2021 TLR: Jul 2023
Phase 2 DESTINY-Lung01  NCT03505710 JapicCTI-183916  AstraZeneca	HER2 overexpressing or HER2 mutant NSCLC, 2L or later	181	Non-randomized, open label HER2 overexpressing NSCLC •DS-8201 6.4mg/kg •DS-8201 5.4mg/kg HER2 mutant NSCLC •DS-8201 6.4mg/kg	Primary endpoint: ORR Secondary endpoint: ORR, DOR, PFS, OS, DCR	JP/US/EU	FPD: May 2018 TLR: Jun 2021  HER2 mutant NSCLC Aug 2022: Approval (US) (with consideration of the interim analysis data of DESTINY-Lung02) May 2020: Breakthrough Therapy Designation (US) Sep 2022: Orphan Drug Designation (JP)  HER2 overexpressing NSCLC Jan 2024: Filing accepted as one of HER2 expressing tumors (US) Jan 2024: Priority Review Designation (US)
Phase 2 DESTINY-Lung02  NCT04644237 jRCT2061200038  AstraZeneca	HER2 mutant NSCLC, 2L or later	152	Randomized, double blind •DS-8201: 6.4mg/kg •DS-8201: 5.4mg/kg	Primary endpoint: ORR Secondary endpoint: ORR, DOR, DCR, PFS, OS, safety	JP/US/EU /Asia	FPD: Mar 2021  Aug 2022: Approval (US) Aug 2023: Approval (JP) Oct 2023: Approval (EU)

## Trastuzumab deruxtecan/DS-8201/T-DXd (HER2-directed ADC)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 1b DESTINY-Lung03  NCT04686305  AstraZeneca	HER2 positive NSCLC, 1L	168	Non-randomized, three-part (safety run-in, dose escalation, dose expansion) •DS-8201 + durvalumab + cisplatin •DS-8201 + durvalumab + carboplatin •DS-8201 + durvalumab + pemetrexed •DS-8201 + durvalumab •DS-8201 + MEDI5752 •DS-8201 + MEDI5752 + carboplatin	Primary endpoint: safety Secondary endpoint: ORR, DOR, DCR, PFS, OS, PK, etc.	US/EU /Asia	FPD: Nov 2021
Phase 3 DESTINY-Lung04  NCT05048797 jRCT2011210058  AstraZeneca	NSCLC with HER2 exon 19 or exon 20 mutation, 1L	264	Randomized, open label •DS-8201 •pemetrexed + pembrolizumab + cisplatin or carboplatin	Primary endpoint: PFS Secondary endpoint: OS, PFS, ORR, DOR, safety, PK, etc.	JP/US/EU /Asia	FPD: Dec 2021
Phase 2 DESTINY-Lung05  NCT05246514  AstraZeneca	NSCLC with HER2 exon 19 or exon 20 mutation, 2L or later	72	Open label •DS-8201	Primary endpoint: ORR Secondary endpoint: ORR, DOR, DCR, PFS, OS, PK, ADA, safety	China	FPD: Aug 2022 TLR: Nov 2023
Phase 2 HUDSON  NCT03334617  AstraZeneca	NSCLC, 2L or later	420	Non-randomized, open label, combination with durvalumab •DS-8201 + durvalumab  * Umbrella study of durvalumab led by AstraZeneca	Primary endpoint: ORR Secondary endpoint: DCR, best percentage change in tumor size, DOR, PFS, OS	US/EU /Asia	FPD: Jun 2020 TLR: Aug 2022

## Trastuzumab deruxtecan/DS-8201/T-DXd (HER2-directed ADC)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 2 DESTINY-CRC02  NCT04744831 jRCT2051200124  AstraZeneca	HER2 overexpressing colorectal cancer, 3L	122	Randomized, double blind •DS-8201 : 6.4mg/kg •DS-8201 : 5.4mg/kg	Primary endpoint: ORR Secondary endpoint: DOR, DCR, PFS, OS, PK, PRO, safety, etc.	JP/US/EU /Asia	FPD: Mar 2021 TLR: Jan 2023 Jan 2024: Filing accepted as one of HER2 expressing tumors (US)  Breakthrough Therapy Designation (US) Jan 2024: Priority Review Designation (US)
Phase 2 DESTINY-PanTumor02  NCT04482309  AstraZeneca	HER2 expressing tumors (bladder cancer, BTC, cervical cancer, endometrial cancer, ovarian cancer, pancreatic cancer, rare tumors)	468	Non-randomized •DS-8201	Primary endpoint: ORR Secondary endpoint: DOR, DCR, PFS, OS, safety, PK, ADA	US/EU /Asia	FPD: Oct 2020 TLR: Jul 2023 Jan 2024: Filing accepted (US)  Sep 2023: Breakthrough Therapy Designation (US) Jan 2024: Priority Review Designation (US)
Phase 1  NCT03523572  BMS	HER2 positive/low breast cancer HER2 positive/low urothelial carcinoma	99	Non-randomized, open label, combination with nivolumab, two-part (dose escalation, dose expansion) •DS-8201 + nivolumab	Primary endpoint: ORR, safety Secondary endpoint: DOR, DCR, PFS, OS, ORR	US/EU	FPD: Aug 2018 TLR: Sep 2021
Phase 1  NCT04042701  MRK	HER2 positive/low breast cancer HER2 expressing/HER2 mutant NSCLC	115	Non-randomized, open label, combination with pembrolizumab •DS-8201 + pembrolizumab	Primary endpoint: safety, ORR Secondary endpoint: DOR, DCR, PFS, TTR, OS	US/EU	FPD: Apr 2020
Phase 1/2a PETRA  NCT04644068  AstraZeneca	Solid tumors	604	Non-randomized, open label, combination with AZD5305 •DS-8201 + AZD5305	Primary endpoint: safety Secondary endpoint: tumor size change, ORR, DOR, PFS, TTR, PK, ADA, etc	US/EU /Asia	FPD: Sep 2022



## Datopotamab deruxtecan/DS-1062/Dato-DXd (TROP2-directed ADC)

Antibody-drug conjugate which is composed of a humanized monoclonal antibody specifically targeting TROP2 (Research collaboration with Sapporo Medical University). TROP2 is an antigen highly expressed on the cell membrane of cancer cells, and a covalently linked drug (payload) via a cleavable linker. Payload is a potent and membrane permeable DNA topoisomerase I inhibitor which enables elimination of both target tumor cells and the surrounding tumor cells. Drug-to-antibody ratio is approximately 4.

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 1 TROPION- PanTumor01  NCT03401385 JapicCTI-173812  AstraZeneca	NSCLC TNBC HR positive, HER2 low or negative breast cancer SCLC Transitional cell carcinoma of the urothelium HER2 negative gastroesophageal cancer Esophageal cancer Prostate cancer, etc.	890	Open label, two-part (dose escalation, dose expansion) •DS-1062	Primary endpoint: safety Secondary endpoint: PK, ADA	JP/US	FPD: Feb 2018
Phase 1/2 TROPION- PanTumor02  NCT05460273  AstraZeneca	NSCLC TNBC	119	Open label •DS-1062	Primary endpoint: ORR Secondary endpoint: ORR, DOR, DCR, BOR, TTR, PFS, OS, safety, PK, etc.	China	FPD: Jul 2022
Phase 2 TROPION- PanTumor03  NCT05489211 jRCT2031220404  AstraZeneca	Endometrial cancer Gastric cancer Castration-resistant prostate cancer Ovarian cancer Colorectal cancer Bladder cancer BTC	670	Open label •DS-1062 •DS-1062 in combination with approved or novel anticancer agents	Primary endpoint: ORR, safety Secondary endpoint: PFS, DOR, DCR, best percentage change in tumor size, ADA, PK, etc.	JP/US/EU /Asia	FPD: Sep 2022

## Datopotamab deruxtecan/DS-1062/Dato-DXd (TROP2-directed ADC)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 3 TROPION-Lung01  NCT04656652 jRCT2071200104  AstraZeneca	NSCLC, 2L/3L	590	Randomized, open label, active control •DS-1062 •Docetaxel	Primary endpoint: PFS, OS Secondary endpoint: PFS, ORR, DOR, TTR, DCR, safety, PK, ADA	JP/US/EU /Asia	FPD: Feb 2021 TLR: disclosed in Jul 2023
Phase 1 TROPION-Lung02  NCT04526691 jRCT2031200193  MRK AstraZeneca	NSCLC (without AGA) Part 1: 3L or later Part 2: 1L/2L	145	Open label, combination with pembrolizumab, two-part (dose escalation, dose expansion) •DS-1062 + pembrolizumab ± platinum chemotherapy	Primary endpoint: safety and tolerability Secondary endpoint: ORR, DOR, PFS, OS, PK, ADA	JP/US/EU /Asia	FPD: Oct 2020
Phase 1 TROPION-Lung04  NCT04612751 jRCT2031200449  AstraZeneca	NSCLC (without AGA), 1L/2L	232	Open label, combination with immunotherapy, two-part (dose escalation, dose expansion) •DS-1062 + durvalumab ± carboplatin •DS-1062 + AZD2936 ± carboplatin •DS-1062 + MEDI5752 ± carboplatin	Primary endpoint: safety and tolerability Secondary endpoint: ORR, DOR, PFS, TTR, OS, PK, ADA, etc.	JP/US/EU	FPD: Mar 2021
Phase 2 TROPION-Lung05  NCT04484142 jRCT2041200097  AstraZeneca	NSCLC (with AGA)	137	Open label •DS-1062	Primary endpoint: ORR Secondary endpoint: DOR, PFS, OS, safety, PK, ADA	JP/US/EU /Asia	FPD: Mar 2021 TLR: Mar 2023

## Datopotamab deruxtecan/DS-1062/Dato-DXd (TROP2-directed ADC)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 3 TROPION-Lung07  NCT05555732 jRCT2061220066  MRK AstraZeneca	non-squamous NSCLC (without AGA and PD-L1 <50%), 1L	975	Randomized, open label, active control •DS-1062 + pembrolizumab + cisplatin or carboplatin •DS-1062 + pembrolizumab •Pembrolizumab + pemetrexed + cisplatin or carboplatin	Primary endpoint: PFS, OS Secondary endpoint: ORR, PFS, DOR, TTR, DCR, TTD, safety, ADA, etc.	JP/US/EU /Asia	FPD: Jan 2023
Phase 3 TROPION-Lung08  NCT05215340 jRCT2061210074  MRK AstraZeneca	NSCLC (without AGA and PD-L1 ≥ 50%), 1L	740	Randomized, open label, active control •DS-1062 + pembrolizumab •Pembrolizumab	Primary endpoint: PFS, OS Secondary endpoint: ORR, PFS, DOR, TTR, DCR, TTD, safety, ADA, etc.	JP/US/EU /Asia	FPD: Mar 2022
Phase 1b/2 BEGONIA  NCT03742102  AstraZeneca	TNBC, 1L	240	Non-randomized, open label, combination with durvalumab •DS-1062 + durvalumab •DS-1062 + durvalumab (patients with PD-L1 positive status)  * Umbrella study of durvalumab led by AstraZeneca	Primary endpoint: safety Secondary endpoint: ORR, PFS, DOR, OS, PK	US/EU /Asia	FPD: May 2021
Phase 3 TROPION-Breast01  NCT05104866 jRCT2031210440  AstraZeneca	HR positive, HER2 low or negative breast cancer, 2L/3L	733	Randomized, open label, active control •DS-1062 •Physician's choice (capecitabine, gemcitabine, eribulin or vinorelbine)	Primary endpoint: PFS, OS Secondary endpoint: ORR, DOR, PFS, DCR, PK, ADA, etc	JP/US/EU /Asia	FPD: Nov 2021 TLR: Sep 2023

## Datopotamab deruxtecan/DS-1062/Dato-DXd (TROP2-directed ADC)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 3 TROPION-Breast02  NCT05374512 jRCT2061220029  AstraZeneca	TNBC, PD-1/PD-L1 inhibitor ineligible, 1L	600	Randomized, open label, active control •DS-1062 * Physician's choice (paclitaxel, nab-paclitaxel, carboplatin, capecitabine, eribulin)	Primary endpoint: PFS, OS Secondary endpoint: ORR, DOR, PFS, TTD, PK, ADA, safety, etc	JP/US/EU /Asia	FPD: Jun 2022
Phase 3 TROPION-Breast03  NCT05629585  AstraZeneca	TNBC with residual invasive disease following neoadjuvant therapy, adjuvant therapy	1,075	Randomized, open label, active control •DS-1062 + durvalumab •DS-1062 •Physician's choice (capecitabine, pembrolizumab, capecitabine + pembrolizumab)	Primary endpoint: IDFS Secondary endpoint: DDFS, OS, IDFS, TTD, fatigue, PK, ADA, safety and tolerability	JP/US/EU /Asia	FPD: Dec 2022
Phase 3 TROPION-Breast04  NCT06112379  AstraZeneca	TNBC or HR low, HER2 low or negative BC, neoadjuvant with durvalumab and adjuvant durvalumab ± chemotherapy	1,728	Randomized, open label, 2 arm, active control •DS-1062 + durvalumab as neoadjuvant, durvalumab ± chemotherapy as adjuvant •pembrolizumab + chemotherapy as neoadjuvant, pembrolizumab ± chemotherapy as adjuvant	Primary endpoint: pCR, EFS Secondary endpoint: OS, DDFS, PROs, PK, ADA, safety	JP/US/EU /Asia	FPD: Nov 2023
Phase 3 TROPION-Breast05  NCT06103864  AstraZeneca	PD-L1 positive TNBC, with or without durvalumab, 1L	625	Randomized, open label, 3 arm, active control •DS-1062 + durvalumab •Physician's choice of chemotherapy in combination with pembrolizumab (paclitaxel, nab-paclitaxel, or gemcitabine + carboplatin) •DS-1062	Primary endpoint: PFS Secondary endpoint: OS, ORR, DOR, PFS by investigator assesment, CBR, TTD, etc.	JP/US/EU /Asia	FPD: Nov 2023

## Datopotamab deruxtecan/DS-1062/Dato-DXd (TROP2-directed ADC)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 1/2a PETRA  NCT04644068  AstraZeneca	Solid tumors	804	Non-randomized, open label, combination with AZD5305 •DS-1062 + AZD5305	Primary endpoint: safety Secondary endpoint: tumor size change, ORR, DOR, PFS, TTR, PK, ADA, etc	JP/US/EU /Asia	FPD: Mar 2022
Phase 2 ORCHARD  NCT03944772  AstraZeneca	EGFR mutated NSCLC, 2L	250	Non-randomized, open label •DS-1062 + osimertinib  * Platform study of osimertinib led by AstraZeneca	Primary endpoint: ORR Secondary endpoint: PFS, DOR, OS, PK, safety, etc.	JP/US/EU /Asia	FPD: Jul 2022
Phase 2 NeoCOAST-2  NCT05061550  AstraZeneca	Resectable, early-stage NSCLC, neoadjuvant	350	Non-randomized, open label •DS-1062 + durvalumab + single agent platinum chemotherapy as neoadjuvant treatment and durvalumab as adjuvant treatment  * Platform study of durvalumab led by AstraZeneca	Primary endpoint: pCR, safety Secondary endpoint: EFS, DFS, ORR, OS, etc.	US/EU /Asia	FPD: Aug 2023

## Patritumab deruxtecan/U3-1402/HER3-DXd (HER3-directed ADC)

Antibody-drug conjugate which is composed of fully human monoclonal antibody specifically targeting HER3, one of the Epidermal Growth Factor Receptor (EGFR) family proteins, and a covalently linked drug (payload) via a cleavable linker. Payload is a potent and membrane permeable DNA topoisomerase I inhibitor which enables elimination of both target tumor cells and the surrounding tumor cells. Drug-to-antibody ratio is approximately 8.

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 1 NCT03260491 JapicCTI-194868 MRK	NSCLC	264	Non-randomized, open label, two-part (dose escalation, dose expansion) •U3-1402	Primary endpoint: safety and tolerability, ORR, PK Secondary endpoint: PK, ADA, ORR, DCR, DOR, TTR, PFS, OS, safety	JP/US/EU /Asia	FPD: Feb 2018
Phase 2 (registrational) HERTHENA-Lung01 NCT04619004 jRCT2031200186 MRK	EGFR mutated NSCLC, 3L	420	Randomized, open label •U3-1402	Primary endpoint: ORR Secondary endpoint: DOR, PFS, ORR, DCR, TTR, OS, safety, etc.	JP/US/EU /Asia	FPD: Feb 2021 TLR: disclosed in Apr 2023 Dec 2023: Filing accepted (US)  Dec 2021: Breakthrough Therapy Designation (US) Real Time Oncology Review Designation (US) Dec 2023: Priority Review Designation (US)
Phase 3 HERTHENA-Lung02 NCT05338970 jRCT2021220002 MRK	EGFR mutated NSCLC, 2L	560	Randomized, open label, active control •U3-1402 •Platinum-based chemotherapy	Primary endpoint: PFS Secondary endpoint: OS, PFS, ORR, DOR, CBR, DCR, safety, etc.	JP/US/EU /Asia	FPD: Aug 2022
Phase 1 NCT04676477 jRCT2031200247 AstraZeneca MRK	EGFR mutated NSCLC, 1/2L	280	Non-randomized, open label, two-part (dose escalation, dose expansion) •U3-1402 + Osimertinib	Primary endpoint: safety and tolerability, ORR Secondary endpoint: ORR, DOR, DCR, TTR, PFS, OS, safety, PK, etc.	JP/US /Asia	FPD: Jun 2021
Phase 2 in prep HERTHENA-PanTumor01 NCT06172478 MRK	melanoma, SCCHN, and HER2-negative gastric cancer	120	Non-randomized, open label •U3-1402	Primary endpoint: ORR Secondary endpoint: safety, DOR, CBR, DCR, TTR, PFS, OS, PK, etc.	JP/US/EU /Asia	

## Ifinatamab deruxtecan/DS-7300/I-DXd (B7-H3-directed ADC)

Antibody-drug conjugate which is composed of fully human monoclonal antibody specifically targeting B7-H3, one of the immunomodulatory molecules belonging to B7 family, and a covalently linked drug (payload) via a cleavable linker. Payload is a potent and membrane permeable DNA topoisomerase I inhibitor which enables elimination of both target tumor cells and the surrounding tumor cells. Drug-to-antibody ratio is approximately 4.

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 1/2 IDeate-PanTumor01  NCT04145622 JapicCTI-194992  MRK	Esophageal squamous cell carcinoma, castration-resistant prostate cancer, sq-NSCLC, SCLC, etc.	195	Non-randomized, open label, two-part (dose escalation, dose expansion) •DS-7300	Primary endpoint: safety and tolerability, antitumor effect Secondary endpoint: PK, etc.	JP/US	FPD: Oct 2019
Phase 2 IDeate-Lung01 (IDeate-1)  NCT05280470 jRCT2041220019  MRK	Extensive-stage SCLC, 2L or later	91	Randomized, open label •DS-7300 : 8mg/kg •DS-7300 : 12mg/kg	Primary endpoint: ORR Secondary endpoint: safety, PFS, DOR, OS, TTR, ORR, DCR, PK, ADA	JP/US/EU /Asia	FPD: Jun 2022  Apr 2023: Orphan Drug Designation (US)
Phase 3 in prep IDeate-Lung02 (IDeate-2)  NCT06203210  MRK	Extensive-stage SCLC, 2L or later	468	Randomized, open label •DS-7300 : 12mg/kg •Physician's choice (topotecan, amrubicin, lurbinectedin)	Primary endpoint: ORR by BICR, OS Secondary endpoint: ORR by investigator, PFS, DOR, DCR, TTR, safety, ADA, etc.	JP/US/EU /Asia	

## Raludotatug deruxtecan/DS-6000/R-DXd (CDH6-directed ADC)

Antibody-drug conjugate which is composed of fully human monoclonal antibody specifically targeting CDH6, one of the cadherin proteins relating to tumor growth and poor prognosis, and a covalently linked drug (payload) via a cleavable linker. Payload is a potent and membrane permeable DNA topoisomerase I inhibitor which enables elimination of both target tumor cells and the surrounding tumor cells. Drug-to-antibody ratio is approximately 8.

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 1 NCT04707248 jRCT2031220075 MRK	Renal cell carcinoma, ovarian cancer	140	Non-randomized, open label, two-part (dose escalation, dose expansion) •DS-6000	Primary endpoint: safety and tolerability Secondary endpoint: PK, ORR, DOR, DCR, etc.	JP/US	FPD: Jan 2021
Phase 2/3 in prep REJOICE-Ovarian01 NCT06161025 MRK	Platinum-resistant ovarian cancer, primary peritoneal cancer, fallopian tube cancer, 2L or later	650	Randomized, open label, two-part (Part A (Phase 2): dose optimization, Part B (Phase 3): comparing efficacy with investigator's choice of chemotherapy) •DS-6000 •Physician's choice (gemcitabine, paclitaxel, topotecan, PLD)	Primary endpoint: ORR by BICR for Part A. PFS, ORR by BICR for Part B Secondary endpoint: ORR by investigator, DOR, PFS (for Part A), DCR, OS, safety, PK, etc.	JP/USEU/ Asia	

## ◆ Next Wave (Oncology Late-Stage Pipeline Products)

### Quizartinib/AC220 (FLT3 inhibitor)

Kinase inhibitor against a receptor-type tyrosine kinase, FLT3. Therapeutic effect for patients with acute myeloid leukemia harboring *FLT3*-ITD mutation is expected.

Brand name: VANFLYTA (JP/US)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 3 QuANTUM-First NCT02668653 JapicCTI-173667	<i>FLT3</i> -ITD positive AML, 1L	539	Randomized, double-blind, placebo-controlled •Quizartinib + chemotherapy •Placebo + chemotherapy	Primary endpoint: OS Secondary endpoint: EFS, etc.	JP/US/EU /Asia	FPD: Sep 2016 TLR: Nov 2021 May 2023: Approval (JP) Jul 2023: Approval (US) Nov 2023: Approval (EU)  Mar 2009: Orphan Drug Designation (US/EU) Fast Track Designation (US) Priority Review Designation (US) Sep 2018: Orphan Drug Designation (JP)



## Pexidartinib/PLX3397 (CSF-1/KIT/FLT3 inhibitor)

The molecular-targeted agent to inhibit CSF-1R, KIT and FLT3 specifically. This agent is expected to reduce tumor cell proliferation and expansion of metastases.

Brand name: TURALIO (US)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 3 NCT04488822	Tenosynovial giant cell tumor	35	Open label •Pexidartinib	Primary endpoint: ORR Secondary endpoint: TVS, ROM, PROMIS, DOR, etc.	Asia	FPD: Sep 2020
Phase 2 NCT04703322 jRCT2041200074	Tenosynovial giant cell tumor	21	Open label •Pexidartinib	Primary endpoint: safety and tolerability, PK, ORR Secondary endpoint: safety, ORR, ROM, PROMIS, DOR, etc.	JP	FPD: Apr 2021

## Valemetostat/DS-3201 (EZH1/2 inhibitor)

Inhibitor of histone methylases, EZH1 and EZH2. Some cancer cells grow dependently on these enzymes.

Brand name: EZHARMIA (JP)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 2 (registrational) NCT04102150 JapicCTI-194964	Adult T-cell leukemia-lymphoma	25	Open label •DS-3201	Primary endpoint: ORR Secondary endpoint: ORR, CR rate, TTR, DOR, PFS, OS, etc.	JP	FPD: Dec 2019 TLR: Jul 2021 Sep 2022: Approval (JP)  Nov 2021: Orphan Drug Designation
Phase 2 (registrational) VALENTINE-PTCL01 NCT04703192 jRCT2071200095	Relapsed/refractory peripheral T-cell lymphoma	176	Non-Randomized, open label •DS-3201	Primary endpoint: ORR Secondary endpoint: DOR, CR rate, safety, etc.	JP/US/EU /Asia	FPD: Jun 2021 TLR: Jun 2023  Apr 2019: SAKIGAKE Designation (JP) Dec 2021: Orphan Drug Designation (US)
Phase 2 NCT04842877 LYSA	Relapsed/refractory B-cell lymphoma	141	Non-Randomized, open label •DS-3201	Primary endpoint: ORR Secondary endpoint: CR rate, PFS, DOR, TTR, safety, PK	EU	FPD: Jun 2021
Phase 1 NCT02732275 JapicCTI-163173	Non-Hodgkin's lymphoma	100	Open label •DS-3201	Primary endpoint: safety, PK, antitumor effect Secondary endpoint: ORR, DCR, DOR, PFS, etc.	JP/US	FPD: Apr 2016

## ◆ Next Wave (Oncology Early-Stage Pipeline Products)

### DS-1001 (Mutant IDH1 inhibitor)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 1 NCT03030066 JapicCTI-163479	Glioma	47	Open label •DS-1001	Primary endpoint: tolerability Secondary endpoint: safety, PK, antitumor effect	JP	FPD: Jan 2017
Phase 2 NCT04458272 JapicCTI-205339	Glioma	25	Open label •DS-1001	Primary endpoint: ORR, safety Secondary endpoint: antitumor effect, TTR, DOR, PFS, OS, PK, etc	JP	FPD: Jul 2020 TLR: Sep 2023

### DS-1055 (anti-GARP antibody)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 1 NCT04419532 JapicCTI-205292	Solid tumors	40	Non-randomized, open label •DS-1055	Primary endpoint: safety and tolerability Secondary endpoint: PK, ADA, etc.	JP/US	FPD: Oct 2020

### DS-1594 (Menin-MLL binding inhibitor)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 1/2 NCT04752163 MD Anderson	Acute myeloid leukemia, acute lymphoblastic leukemia	122	Non-randomized, open label •DS-1594 •DS-1594 + venetoclax + azacitidine •DS-1594 + mini HCVD •DS-1594 + posaconazol or voriconazole	Primary endpoint: safety and tolerability, CR rate Secondary endpoint: composite CR rate, MLFS rate, PR rate, ORR, DOR, EFS, OS, mortality rate, etc.	US	FPD: Apr 2021

### DS-9606 (Target undisclosed ADC)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 1 NCT05394675	Solid tumors	125	Non-randomized, open label •DS-9606	Primary endpoint: safety and tolerability, ORR Secondary endpoint: PK, DOR, DCR, TTR, PFS, ADA, etc.	US/EU	FPD: Jun 2022

### DS-1103 (anti-SIRP $\alpha$ antibody)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 1 NCT05765851	HER2 expressing or mutant solid tumors (dose escalation part), HER2-low BC (dose expansion part)	78	Non-randomized, open label, two-part (dose escalation, dose expansion) •DS-1103 + DS-8201	Primary endpoint: safety and tolerability, ORR Secondary endpoint: ORR, DCR, CBR, DOR, PK, ADA, etc.	US/EU	FPD: Jun 2023

### DS-3939 (TA-MUC1-directed ADC)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 1/2 NCT05875168 jRCT2031230233 Glycotope GmbH	Solid tumors	430	Non-randomized, open label, two-part (dose escalation, dose expansion) •DS-3939	Primary endpoint: safety and tolerability, ORR Secondary endpoint: ORR, DCR, DOR, TTR, PFS, OS, PK, ADA, etc.	JP/US	FPD: Sep 2023

### DS-1471 (anti-CD147 antibody)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 1 NCT06074705 jRCT2031230234	Solid tumors	80	Non-randomized, open label, two-part (dose escalation, dose expansion) •DS-1471	Primary endpoint: safety and tolerability Secondary endpoint: BOR, ORR, DCR, DOR, TTR, PFS, OS, PK, ADA etc.	JP	FPD: Sep 2023

## ◆ Next Wave (Specialty Medicines Late-Stage Pipeline Products)

### Mirogabalin/DS-5565 ( $\alpha_2\delta$ ligands)

The pain therapy agent to reduce the neurotransmitter release from nerve terminals. This agent is expected to show the good balanced efficacy and safety profile.

Brand name: TARLIGE (JP)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 3 NCT04094662	Diabetic peripheral neuropathic pain	393	Randomized, double-blind, placebo-controlled • Mirogabalin • Placebo	Primary endpoint: average daily pain score Secondary endpoint: visual analogue scale, average daily sleep interference score	China	FPD: Sep 2019  Jan 2023: Filing accepted (CN)

### Esaxerenone/CS-3150 (MR blocker)

The agent inhibits aldosterone binding to Mineralocorticoid Receptor (MR) which stimulate the sodium absorption into kidney. This agent is expected to exhibit antihypertensive and organ-protective effect.

Brand name: MINNEBRO (JP)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 3 JapicCTI-173695 Exelixis, Inc.	Diabetic nephropathy	400	Randomized, double-blind, placebo-controlled • Esaxerenone • Placebo	Primary endpoint: UACR remission rate Secondary endpoint: change rate in UACR and eGFR, etc.	JP	FPD: Sep 2017 TLR: Jul 2019

## ◆ Next Wave (Specialty Medicines Early-Stage Pipeline Products)

### DS-1211 (TNAP inhibitor)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 2 NCT05569252	Pseudoxanthoma elasticum	64	Randomized, double-blind, placebo-controlled •DS-1211	Primary endpoint: safety, pharmacodynamic (PD) dose response Secondary endpoint: PK	US/EU	FPD: Nov 2022

### DS-7011 (anti-TLR7 antibody)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 1b/2 NCT05638802	Adult subjects with SLE including cutaneous lupus erythematosus (CLE)	24	Randomized, double-blind, placebo-controlled •DS-7011	Primary endpoint: safety and tolerability Secondary endpoint: PK, efficacy, immunogenicity	US	FPD: Jul 2023

### DS-2325 (KLK5 inhibitor)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 1b/2 NCT05979831	Netherton syndrome	12	Randomized, Double-Blind, Placebo-Controlled •DS-2325 •Placebo	Primary endpoint: safety Secondary endpoint: PK, Mean Ichthyosis Area Severity Index (IASI) Scores, Mean Investigator Global Assessment (IGA) Scores, etc.	EU	Dec 2022: Orphan Drug Designation (US) Feb 2023: Fast Track Designation (US) May 2023: Rare Pediatric Disease Designation (US)  FPD: Dec 2023

## ◆ Next Wave (Vaccine)

### DS-5670 (original strain) (COVID-19 mRNA vaccine)

mRNA vaccine against COVID-19 designed to produce antibodies against the receptor binding domain (RBD) of the spike protein of SARS-CoV-2.  
Brand name: DAICHIRONA (JP)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 1/2/3 jRCT2071210106	Healthy adults who have completed primary vaccination of approved COVID-19 vaccine, prevention of COVID-19	5,028	Randomized, single-blind, active-controlled, two-part (dose confirmation and non-inferiority) ·DS-5670 (original strain) ·Comirnaty® ·Spikevax®	Primary endpoint: immunogenicity (GMFR of neutralizing activity), safety Secondary endpoint: immunogenicity, safety	JP	FSD: Jan 2022 TLR: Nov 2022 Aug 2023: Approved (JP)

### DS-5670 (mutant strain) (COVID-19 mRNA vaccine)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 3 jRCT2071220111	Healthy volunteers 12 years and older who have completed primary vaccination of approved COVID-19 vaccine, prevention of COVID-19	1,400	Randomized, single-blind, active-controlled, Main Study and Substudy A (dose validity examination), Sub study B (examination for immunogenicity and safety) ·DS-5670 (omicron variant-adapted bivalent vaccine (original/ omicron BA.4-5)) ·Comirnaty® RTU (original/ omicron BA.4-5)	Primary endpoint: Main Study: GMT of blood neutralizing activity against SARS-CoV-2 (Omicron strain) and seroresponse rate at 4 weeks after study drug administration Sub Study A, Sub Study B: not applicable.  Secondary endpoint: Main Study: GMT of blood neutralizing activity against SARS-CoV-2 (original strain) and seroresponse rate at 4 weeks after study drug administration, incidence of COVID-19 for 52 weeks after study drug administration, safety Sub Study A, Sub Study B: safety	JP	FSD: May 2023 TLR: Sep 2023 Sep 2023: Filing accepted for monovalent omicron XBB.1.5 (JP) Nov 2023: Approval for monovalent omicron XBB.1.5 (JP)

## DS-5670 (mutant strain) (COVID-19 mRNA vaccine)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 3 jRCT2031230424	Healthy volunteers 12 years and older, prevention of COVID-19, single dose	690	Randomized, double-blind, active-controlled ·DS-5670 (XBB.1.5 strain variant-adapted bivalent vaccine) ·Comirnaty® RTU	Primary endpoint: GMT and seroresponse rate of blood neutralising activity against SARS-CoV-2 (Omicron XBB.1.5) at 4 weeks after the administration in adults and children aged 12 years and older with at least one of SARS-CoV-2 infection history and SARS-CoV-2 vaccination history  Secondary endpoint: GMT and seroresponse rate of blood neutralising activity against SARS-CoV-2 (Omicron XBB.1.5) at 4 weeks after the administration in adults and children aged 12 years and older regardless of SARS-CoV-2 infection history and SARS-CoV-2 vaccination history	JP	FSD: Jan 2024
Phase 2/3 jRCT2031220665	Children aged 5 to 11 years who have completed primary vaccination of approved COVID-19 vaccine, prevention of COVID-19	210	Randomized, double-blind, active-controlled, non-inferiority ·DS-5670 (omicron variant-adapted bivalent vaccine (original/ BA.4-5)) ·Comirnaty® for 5 to 11 years old	Primary endpoint: GMT of blood neutralizing activity against SARS-CoV-2 (Omicron strain) and seroresponse rate at 4 weeks after study drug administration.  Secondary endpoint: GMT of blood neutralizing activity against SARS-CoV-2 (original strain) and seroresponse rate at 4 weeks after study drug administration, Incidence of COVID-19 for 52 weeks after study drug administration, safety	JP	FSD: May 2023

## VN-0102/JVC-001 (mixed measles-mumps-rubella vaccines)

Trivalent mixed vaccine (MMR vaccine) containing three attenuated viruses of measles, mumps and rubella, which has not been approved in Japan.

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 3 JapicCTI-205118	Prevention of measles, mumps and rubella in healthy Japanese children aged 12 months or more and less than 24 months	840	Randomized, double-blind, active-controlled •VN-0102/ JVC-001 •Dry Live Attenuated Measles Rubella vaccine, Freeze-dried Live Attenuated Mumps vaccine	Primary endpoint: Seroprotection rates for measles, mumps and rubella Secondary endpoint: Seroconversion rates for measles, mumps, and rubella	JP	FSD: Feb 2020 LSD: Sep 2020

## VN-0200 (RS virus vaccine)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 2 NCT05547087 jRCT2071220051	Healthy elderly, prevention of respiratory syncytial (RS) virus infection	340	Randomized, double-blind, dose-comparison •VN-0200	Primary endpoint: immunogenicity Secondary endpoint: safety	JP	FSD: Oct 2022



◆ Stage-up Projects (Major Changes from the FY2023 Q2 Financial Announcement in October 2023)

Generic Name/Project Code Number Mechanism of action	Target Indication	Current Stage	Note
Quizartinib/AC220 FLT3 inhibitor	FLT3-ITD positive AML, 1L	Approved	EU, QuANTUM-First
DS-5670 (mutant strain) COVID-19 mRNA vaccine	Prevention of COVID-19 (booster vaccination, omicron variant-adapted vaccine (XBB.1.5), 12 years and over)	Approved	Japan
Trastuzumab deruxtecan/DS-8201/T-DXd HER2-directed ADC	HER2 expressing tumors	Filed	US, DESTINY-PanTumor02, DESTINY-CRC02 and DESTINY-Lung01 etc
Patritumab deruxtecan/U3-1402/HER3-DXd HER3-directed ADC	EGFR mutated NSCLC, 3L	Filed	US, HERTHENA-Lung01
Datopotamab deruxtecan/DS-1062/Dato-DXd TROP2-directed ADC	TNBC or HR low, HER2 low or negative BC, neoadjuvant with durvalumab and adjuvant durvalumab ± chemotherapy	Ph3	JP/US/EU/Asia, TROPION-Breast04
Datopotamab deruxtecan/DS-1062/Dato-DXd TROP2-directed ADC	PD-L1 positive TNBC, with or without durvalumab, 1L	Ph3	JP/US/EU/Asia, TROPION-Breast05
DS-5670 (mutant strain) COVID-19 mRNA vaccine	Prevention of COVID-19 (omicron variant-adapted vaccine (XBB.1.5), 12 years and over), single dose	Ph3	JP

◆ **Stage-up Projects (Major Changes from the FY2023 Q2 Financial Announcement in October 2023)**

Generic Name/Project Code Number Mechanism of action	Target Indication	Current Stage	Note
Patritumab deruxtecan/U3-1402/HER3-DXd HER3-directed ADC	melanoma, squamous cell carcinomas of the head and neck (SCCHN), and HER2-negative gastric cancer	Ph2 prep	JP/US/EU/Asia, HERTHENA-PanTumor01
Ifinatamab deruxtecan/DS-7300/ I-DXd B7-H3-directed ADC	ES-SCLC, 2L or later	Ph3 prep	JP/US/EU/Asia, IDeate-Lung02 (IDeate-2)
DS-6000/R-DXd CDH6-directed ADC	Platinum-resistant ovarian cancer, primary peritoneal cancer, fallopian tube cancer, 2L or later	Ph2/3 prep	JP/US/EU/Asia, REJOICE-Ovarian01
DS-2325 KLK5 inhibitor	Netherton syndrome	Ph1b/2	EU